This is a Validated Antibody Database (VAD) review about human FOXP3, based on 295 published articles (read how Labome selects the articles), using FOXP3 antibody in all methods. It is aimed to help Labome visitors find the most suited FOXP3 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
FOXP3 synonym: AIID; DIETER; IPEX; JM2; PIDX; XPID

Invitrogen
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 5g
Invitrogen FOXP3 antibody (eBioscience, 17-4776-42) was used in flow cytometry on human samples (fig 5g). J Immunother Cancer (2022) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; fig s11
Invitrogen FOXP3 antibody (eBioscience -Thermo Fisher Scientific, 41-4777-82) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig s11). Nat Commun (2022) ncbi
mouse monoclonal (150D/E4)
  • flow cytometry; mouse; loading ...; fig s1i
Invitrogen FOXP3 antibody (eBioscience, 12-4774-42) was used in flow cytometry on mouse samples (fig s1i). Front Immunol (2022) ncbi
domestic rabbit monoclonal (SP97)
  • immunohistochemistry; human; 1:10; fig 4a
Invitrogen FOXP3 antibody (Thermo Fischer, MA5-16365) was used in immunohistochemistry on human samples at 1:10 (fig 4a). Nat Commun (2021) ncbi
mouse monoclonal (3G3)
  • flow cytometry; mouse; loading ...; fig s1a, s4f
Invitrogen FOXP3 antibody (eBioscience, 3G3) was used in flow cytometry on mouse samples (fig s1a, s4f). J Immunother Cancer (2021) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; mouse; loading ...; fig 2f
Invitrogen FOXP3 antibody (eBioscience, 12-4777-42) was used in flow cytometry on mouse samples (fig 2f). J Autoimmun (2021) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 6c
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 6c). Cell Death Dis (2020) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig s6a
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig s6a). J Clin Invest (2020) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 2a
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 2a). Arthritis Res Ther (2020) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:100; loading ...; fig 2b
Invitrogen FOXP3 antibody (eBioscience, 14-4777) was used in immunohistochemistry on human samples at 1:100 (fig 2b). Cancer Immunol Immunother (2020) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; loading ...; fig 1g
Invitrogen FOXP3 antibody (Thermo Fisher, PA1-46126) was used in immunohistochemistry - paraffin section on human samples (fig 1g). Cancer Med (2020) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 1a
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 1a). Front Immunol (2019) ncbi
mouse monoclonal (236a/E7)
  • mass cytometry; human; loading ...; fig 2b
Invitrogen FOXP3 antibody (ThermoFisher, 14-4777-82) was used in mass cytometry on human samples (fig 2b). Cell (2019) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig s7a
Invitrogen FOXP3 antibody (Thermo Fisher, 25-4777-41) was used in flow cytometry on human samples (fig s7a). Cell (2019) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; mouse; loading ...; fig s7c
Invitrogen FOXP3 antibody (Invitrogen, 11-4777-42) was used in flow cytometry on mouse samples (fig s7c). Cell Metab (2019) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 1a
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 1a). Proc Natl Acad Sci U S A (2019) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 2a
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2a). Cancer (2019) ncbi
rat monoclonal (PCH101)
  • immunohistochemistry - frozen section; human; loading ...; fig 2c
Invitrogen FOXP3 antibody (eBiosciences, PCH101) was used in immunohistochemistry - frozen section on human samples (fig 2c). J Infect Dis (2018) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - frozen section; human; fig 1a
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - frozen section on human samples (fig 1a). J Exp Med (2018) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; mouse; fig s2b
Invitrogen FOXP3 antibody (eBioscience, 12-4777-42) was used in flow cytometry on mouse samples (fig s2b). Cell (2018) ncbi
rat monoclonal (PCH101)
  • flow cytometry; mouse; loading ...; fig 7a
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on mouse samples (fig 7a). J Clin Invest (2018) ncbi
mouse monoclonal (150D/E4)
  • flow cytometry; mouse; loading ...; fig 5c
Invitrogen FOXP3 antibody (eBioscience, 150D/E4) was used in flow cytometry on mouse samples (fig 5c). Cell Metab (2018) ncbi
mouse monoclonal (eBio7979 (221D/D3))
  • immunohistochemistry - paraffin section; human; loading ...; fig 5b
Invitrogen FOXP3 antibody (eBioscience, 14-7979) was used in immunohistochemistry - paraffin section on human samples (fig 5b). Int J Cancer (2018) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; 1:100; fig 1a
Invitrogen FOXP3 antibody (eBioscience, 12-4776-42) was used in flow cytometry on human samples at 1:100 (fig 1a). Nat Commun (2018) ncbi
domestic rabbit recombinant (5H10L18)
  • immunohistochemistry - paraffin section; mouse; 1:100; loading ...; fig 5a
  • western blot; mouse; 1:1000; loading ...; fig 5c
  • western blot; human; 1:1000; loading ...; fig 4b
Invitrogen FOXP3 antibody (Thermo Scientific, 700914) was used in immunohistochemistry - paraffin section on mouse samples at 1:100 (fig 5a), in western blot on mouse samples at 1:1000 (fig 5c) and in western blot on human samples at 1:1000 (fig 4b). Br J Pharmacol (2018) ncbi
mouse monoclonal (eBio7979 (221D/D3))
  • western blot; mouse; loading ...; fig 1d
In order to study the role of hypercholesterolemia in T cell receptor signaling and regulatory T cell population, Invitrogen FOXP3 antibody (eBioscience, eBio7979) was used in western blot on mouse samples (fig 1d). Sci Rep (2017) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 5a
Invitrogen FOXP3 antibody (ebioscience, PCH101) was used in flow cytometry on human samples (fig 5a). Sci Rep (2017) ncbi
rat monoclonal (PCH101)
  • mass cytometry; human; loading ...; fig 2a
In order to investigate the immune composition of tumor microenvironment in hepatocellular carcinoma, Invitrogen FOXP3 antibody (eBiosciences, PCH101) was used in mass cytometry on human samples (fig 2a). Proc Natl Acad Sci U S A (2017) ncbi
rat monoclonal (PCH101)
  • immunohistochemistry; human; loading ...; fig 8a
In order to investigate the tumor microenvironment in tertiary lymphoid organs of prostate cancer patients, Invitrogen FOXP3 antibody (ebioscience, PCH101) was used in immunohistochemistry on human samples (fig 8a). Front Immunol (2017) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 1f
In order to study the oncogenic role of ERK1 in glioma, Invitrogen FOXP3 antibody (ebioscience, 12-4776) was used in flow cytometry on human samples (fig 1f). J Immunol (2017) ncbi
mouse monoclonal (150D/E4)
  • chromatin immunoprecipitation; mouse; fig 2b
Invitrogen FOXP3 antibody (eBioscience, 14-4774-82) was used in chromatin immunoprecipitation on mouse samples (fig 2b). Cell Metab (2017) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...
In order to find that oral administration of a selective Rho-associated kinase 2 inhibitor, KD025, reduces psoriasis area in 46% of patients with psoriasis vulgaris, Invitrogen FOXP3 antibody (eBioscience, 25-4777) was used in flow cytometry on human samples . J Immunol (2017) ncbi
rat monoclonal (PCH101)
  • western blot; human; fig 2g
In order to examine the effect of glucose-6-phosphate transporter mutation on immune cell homeostasis and CD4+ T cell functions, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in western blot on human samples (fig 2g). J Immunol (2017) ncbi
mouse monoclonal (150D/E4)
  • western blot; human; fig 2g
In order to examine the effect of glucose-6-phosphate transporter mutation on immune cell homeostasis and CD4+ T cell functions, Invitrogen FOXP3 antibody (eBioscience, 150D/E4) was used in western blot on human samples (fig 2g). J Immunol (2017) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 3a
In order to investigate origin of tumor-infiltrating T regulatory cells in breast cancer samples, Invitrogen FOXP3 antibody (Thermo Fisher Scientific, 17-4777) was used in flow cytometry on human samples (fig 3a). Cell Res (2017) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 6f
In order to investigate origin of tumor-infiltrating T regulatory cells in breast cancer samples, Invitrogen FOXP3 antibody (Thermo Fisher Scientific, 12-4776) was used in flow cytometry on human samples (fig 6f). Cell Res (2017) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 3b
Invitrogen FOXP3 antibody (eBiosciences, 236A/E7) was used in flow cytometry on human samples (fig 3b). J Immunol (2017) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 2
In order to examine the potential of IL-2 to enhance T regulatory cell therapy, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2). Clin Exp Immunol (2017) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 3b
In order to characterize the periferal blood lymphocytes phenotype in tacrolimus-treated liver transplanted patients., Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 3b). Med Princ Pract (2017) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 2e
In order to observe that the use of chimeric antigen receptor technology is a clinically applicable refinement of regulatory T cell therapy for organ transplantation, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2e). Am J Transplant (2017) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 1a
In order to develop a method to assess the capacity of human regulatory T cells to suppress IgM production from an immature human B cell line, Invitrogen FOXP3 antibody (eBioscience, 48-4777-42) was used in flow cytometry on human samples (fig 1a). J Immunol Methods (2017) ncbi
mouse monoclonal (150D/E4)
  • flow cytometry; mouse; loading ...
In order to study the role of MCH I in natural killer cell tolerance and hyporesponsiveness, Invitrogen FOXP3 antibody (eBioscience, 150D/E4) was used in flow cytometry on mouse samples . J Immunol (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; loading ...; fig 6
  • flow cytometry; human; loading ...; fig 1a
In order to establish the T Cell receptor-inducible costimulator as a promising target for direct T regulatory cell-targeting therapeutic agents for gastric cancer, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - paraffin section on human samples (fig 6) and in flow cytometry on human samples (fig 1a). Int J Cancer (2017) ncbi
mouse monoclonal (eBio7979 (221D/D3))
  • western blot; human; loading ...; fig 1a
In order to show reverse post-translational regulation of HIF-1alpha by Foxp3, Invitrogen FOXP3 antibody (eBioscience, eBio7979) was used in western blot on human samples (fig 1a). Oncotarget (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
  • immunocytochemistry; human; loading ...; fig 4b
Invitrogen FOXP3 antibody (eBiosciences, PCH101) was used in flow cytometry on human samples and in immunocytochemistry on human samples (fig 4b). J Exp Med (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...
In order to assess how ABCG1 loss in T cells affects atherosclerosis, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . J Clin Invest (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 4b
In order to report that patients with PTEN mutations experience autoimmunity and lymphoid hyperplasia, Invitrogen FOXP3 antibody (NatuTec, PCH101) was used in flow cytometry on human samples (fig 4b). J Allergy Clin Immunol (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:100; fig 2
Invitrogen FOXP3 antibody (eBioscience, 14-4777-82) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2). J Transl Med (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:150; fig st1
In order to study the prognostic value of the ratio of CD8 to Treg tumor-infiltrating lymphocyte in bladder cancer, Invitrogen FOXP3 antibody (ebioscience, 14-4777) was used in immunohistochemistry on human samples at 1:150 (fig st1). Oncoimmunology (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig s1
In order to show that ATG16L1 and NOD2 are required for Bacteroides fragilis-mediated protection from colitis, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig s1). Science (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...
In order to study the role of T regulatory cells in patients with immune thrombocytopenic purpura, Invitrogen FOXP3 antibody (eBioscience, 12-4776) was used in flow cytometry on human samples . Turk J Haematol (2016) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...
In order to test if the two hematopoietic systems in patients with mixed chimerism remain functional and study immunological differences, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . PLoS ONE (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; 1:20; tbl 2
Invitrogen FOXP3 antibody (eBioscience, 12-4776-42) was used in flow cytometry on human samples at 1:20 (tbl 2). Oncoimmunology (2016) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 1a
In order to explore the role of the JAK/STAT pathway in controlling Foxp3 in regulatory T cells, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 1a). PLoS ONE (2016) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 2c
In order to study the pharmacologic inhibition of PI3K and MEK pathways in mixed cultures of human mononuclear cells., Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 2c). Am J Transplant (2016) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; fig 4
In order to develop an HLA-A2-specific chimeric antigen receptor and use it to generate alloantigen-specific human T regulatory cells, Invitrogen FOXP3 antibody (eBiosciences, 12-4777-42) was used in flow cytometry on human samples (fig 4). J Clin Invest (2016) ncbi
mouse monoclonal (150D/E4)
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
In order to analyze differentially expressed granzyme inhibitors in pediatric primitive neuroectodermal tumors of the central nervous system, Invitrogen FOXP3 antibody (Ebioscience, 150D/E4) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). PLoS ONE (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 3c
In order to assess the impact of neoantigen intratumor heterogeneity on antitumor immunity, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 3c). Science (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, 12-4776) was used in flow cytometry on human samples . Immunity (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 1a
In order to examine the relationship between prolactin and T regulatory cells in patients with systemic lupus erythematosus, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 1a). Medicine (Baltimore) (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 8a
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 8a). PLoS Pathog (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 4d
In order to study the role of human head and neck squamous cell carcinoma-associated semaphorin 4d in myeloid-derived suppressor cells, Invitrogen FOXP3 antibody (eBioscience, 12-4776-42) was used in flow cytometry on human samples (fig 4d). J Immunol (2016) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 3a
In order to demonstrate that TGF-beta induces the differentiation of human CXCL13-producing CD4 positive T cells from naive CD4 positive T cells, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 3a). Eur J Immunol (2016) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; rhesus macaque; loading ...; fig 5
In order to describe a selective CD28 antagonist for treatment of rheumatoid arthritis, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on rhesus macaque samples (fig 5). Clin Exp Immunol (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human
In order to study hepatocellular carcinoma and ectopic lymphoid structures function as microniches for tumor progenitor cells, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - paraffin section on human samples . Nat Immunol (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - frozen section; human; 1:100; fig 1
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - frozen section on human samples at 1:100 (fig 1). Nat Commun (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 4
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 4). Haematologica (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
In order to elucidate the prognosis of gastric cancer by tumor-infiltrating immune cells, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). Medicine (Baltimore) (2015) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; fig 8
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 8). J Clin Invest (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to determine the proportions, phenotype, survival, and apoptotic susceptibility of Tregs in sarcoidosis, Invitrogen FOXP3 antibody (eBiosciences, PCH101) was used in flow cytometry on human samples . Respir Res (2015) ncbi
mouse monoclonal (236a/E7)
  • immunocytochemistry; pigs
  • immunohistochemistry; pigs ; 1:50
In order to discuss the role of nucleocapsid-induced IL-10 production and generation of PRRSV-specific Tregs, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunocytochemistry on pigs samples and in immunohistochemistry on pigs samples at 1:50. Vaccine (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human
In order to elucidate the role of IL-10 in human papillomavirus infection, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - paraffin section on human samples . Immunology (2015) ncbi
rat monoclonal (PCH101)
  • immunohistochemistry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in immunohistochemistry on human samples . World J Urol (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to investigate the primary inflammatory and regulatory T cell responses induced by BCG vaccination in adults, Invitrogen FOXP3 antibody (eBioscience, clone PCH101) was used in flow cytometry on human samples . Clin Vaccine Immunol (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 2b
In order to elucidate Th17 cell polarization, depletion, and restoration in response to HIV infection and antiretroviral therapy, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2b). Retrovirology (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig st1
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig st1). Infect Immun (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; 1 ul/test
In order to analyze mucosal pinch biopsies collected predominantly during colonoscopies, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples at 1 ul/test. J Immunol Methods (2015) ncbi
mouse monoclonal (150D/E4)
  • flow cytometry; mouse; fig 3
Invitrogen FOXP3 antibody (eBioscience, 150D/E4) was used in flow cytometry on mouse samples (fig 3). PLoS ONE (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 6
In order to describe the phenotype and functional potential of metastatic differentiated thyroid cancer-associated PD-1 positive T cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 6). Cancer Immunol Res (2015) ncbi
mouse monoclonal (eBio7979 (221D/D3))
  • western blot; mouse; 1:500; fig 5,6
Invitrogen FOXP3 antibody (eBioscience, eBio7979) was used in western blot on mouse samples at 1:500 (fig 5,6). Nat Commun (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 2
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2). Cell Res (2015) ncbi
mouse monoclonal (150D/E4)
  • flow cytometry; rat; fig 1
Invitrogen FOXP3 antibody (eBiosciences, 150D/E4) was used in flow cytometry on rat samples (fig 1). Mol Vis (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 4
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 4). Nat Immunol (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 2
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2). Mol Med Rep (2015) ncbi
mouse monoclonal (eBio7979 (221D/D3))
  • western blot; mouse
In order to identify DUBA as a suppressor of IL-17 production in T cells, Invitrogen FOXP3 antibody (eBiosciences, eBio7979) was used in western blot on mouse samples . Nature (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBiosciences, PCH101) was used in flow cytometry on human samples . J Neuroimmunol (2014) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . Hum Immunol (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . Hum Immunol (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . J Immunol (2015) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . J Immunol (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (e-Bioscience, PCH101) was used in flow cytometry on human samples . Nat Commun (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to examine the role of TLR7 in HIV-infected CD4 positive T cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . Nat Immunol (2015) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 5
In order to study the immune effects of tadalafil in patients with head and neck squamous cell carcinoma., Invitrogen FOXP3 antibody (e-Bioscience, PCH101) was used in flow cytometry on human samples (fig 5). Clin Cancer Res (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . J Immunol (2014) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . J Immunol (2014) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human
Invitrogen FOXP3 antibody (eBioscience, 14-4777-82) was used in immunohistochemistry - paraffin section on human samples . J Immunol (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 3a
In order to show that latency-associated peptide and glycoprotein A repetitions predominant identify human antigen-specific T regulatory cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 3a). Eur J Immunol (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 1
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 1). Immunology (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to determine the presence, frequency, association to other immune parameters, and functional properties of circulating CD14(+) cells lacking HLA-DR expression in patients with untreated chronic lymphocytic leukemia, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . Blood (2014) ncbi
rat monoclonal (PCH101)
  • immunocytochemistry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in immunocytochemistry on human samples . Eur J Immunol (2014) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
In order to characterize preterm infants and alterations found in regulatory T cell subpopulations, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
  • immunocytochemistry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples and in immunocytochemistry on human samples . Mol Oncol (2014) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, clone 236A/E7) was used in flow cytometry on human samples . Mol Ther (2014) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
In order to examine human differentiated effector CD4(+) T cells that are defined by low levels of IL-2 and IL-7 receptors, Invitrogen FOXP3 antibody (eBioscience, 236-A/E7) was used in flow cytometry on human samples . Cancer Res (2014) ncbi
rat monoclonal (PCH101)
  • immunocytochemistry; human; 1:200
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in immunocytochemistry on human samples at 1:200. J Crohns Colitis (2014) ncbi
mouse monoclonal (eBio7979 (221D/D3))
  • immunohistochemistry - paraffin section; domestic sheep; 1:250
In order to test if detrimental inflammatory response of the fetal gut results from local or systemic inflammatory responses, Invitrogen FOXP3 antibody (eBioscience, 14-7979-82) was used in immunohistochemistry - paraffin section on domestic sheep samples at 1:250. Am J Physiol Gastrointest Liver Physiol (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; African green monkey; 1:20; fig s6
In order to decipher how susequent acute infection is supressed in T cell responses after exposure to subinfectious hepatitis C virus, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on African green monkey samples at 1:20 (fig s6). Nat Med (2013) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 2b
In order to test if low immune activation contributes to the viremic slow progressor phenotype, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2b). AIDS Res Hum Retroviruses (2013) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; 1:50; fig 1
In order to determine the localization of CD4 positive T cells subsets in the healthy intestine, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples at 1:50 (fig 1). PLoS ONE (2012) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 1
In order to use PI16 to identify a subset of migratory functional memory T regulatory cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 1). Cell Immunol (2012) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 3a
In order to test if low-dose interleukin-2 enhances T regulatory cells and suppresses chronic graft-versus-host disease, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 3a). N Engl J Med (2011) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 1a
In order to study the role of T regulatory cells in HIV infection, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 1a). J Virol (2011) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:1600
In order to report the immune responses in the parietal pleura of patients with tuberculous pleurisy and compare them with nonspecific pleuritis, Invitrogen FOXP3 antibody (eBioscience, 144-777) was used in immunohistochemistry on human samples at 1:1600. PLoS ONE (2011) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:40; fig S5B
In order to examine tumor and nonadjacent normal breast tissue from women with breast cancer, who either had or had not received neoadjuvant chemotherapy before surgery, Invitrogen FOXP3 antibody (eBioscience, 14-4777-82) was used in immunohistochemistry on human samples at 1:40 (fig S5B). Proc Natl Acad Sci U S A (2012) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig S5D
In order to examine tumor and nonadjacent normal breast tissue from women with breast cancer, who either had or had not received neoadjuvant chemotherapy before surgery, Invitrogen FOXP3 antibody (eBioscience, 15-4776-42) was used in flow cytometry on human samples (fig S5D). Proc Natl Acad Sci U S A (2012) ncbi
mouse monoclonal (eBio7979 (221D/D3))
  • immunohistochemistry - paraffin section; human; 1:50; tbl 2
In order to identify biomarkers to distinguish between true recurrence and new primary cases of ipsilateral breast tumor recurrence, Invitrogen FOXP3 antibody (eBioscience, eBio7979) was used in immunohistochemistry - paraffin section on human samples at 1:50 (tbl 2). Breast Cancer (Auckl) (2011) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; rat; 50 ug/ml; tbl 2
In order to characterize bone marrow-derived mesenchymal stem cells from patients with ankylosing spondylitis, Invitrogen FOXP3 antibody (eBioscience, 236A) was used in flow cytometry on rat samples at 50 ug/ml (tbl 2). Arthritis Res Ther (2011) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig s1
In order to identify immunologic correlates of immune reconstitution inflammatory syndrome in HIV patients, Invitrogen FOXP3 antibody (eBioscience, (clone PCH101)) was used in flow cytometry on human samples (fig s1). Blood (2010) ncbi
rat monoclonal (PCH101)
  • immunohistochemistry; human; 1:200; fig 2
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in immunohistochemistry on human samples at 1:200 (fig 2). J Clin Endocrinol Metab (2010) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; mouse; fig 3
In order to compare the therapeutic efficacy of CD19-specific human primary T cells that constitutively express gamma(c)-cytokines, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on mouse samples (fig 3). Blood (2010) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 1
In order to study T regulatory cells in inflamed human liver samples, Invitrogen FOXP3 antibody (eBioscience, PCH 101) was used in flow cytometry on human samples (fig 1). J Immunol (2010) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to identify biomarkers in the first synovial fluid aspirate obtained from children with oligoarticular juvenile idiopathic arthritis, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . Arthritis Rheum (2010) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to report that human Tregs promote the generation of myeloid dendritic cells which abrogate post transplant lethality, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . PLoS Biol (2010) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 4
In order to discuss the role of T regulatory cells in systemic sclerosis and morphoea, Invitrogen FOXP3 antibody (eBiosciences, PCH101) was used in flow cytometry on human samples (fig 4). Br J Dermatol (2010) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 1
In order to examine the therapeutic potential of anti-CD137 mAb in lymphoma, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 1). Blood (2009) ncbi
mouse monoclonal (eBio7979 (221D/D3))
  • western blot; mouse; 2 ug/ml; fig 7
Invitrogen FOXP3 antibody (eBioscience, eBio7979) was used in western blot on mouse samples at 2 ug/ml (fig 7). J Immunol (2009) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:100; fig 8
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry on human samples at 1:100 (fig 8). J Immunol (2009) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to determine the role of CD59 on human CD4+ T cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . J Immunol (2009) ncbi
mouse monoclonal (eBio7979 (221D/D3))
  • immunohistochemistry; human; 1:50; fig 2
In order to study autoantibodies and tumor-infiltrating T cells in epithelial ovarian cancer, Invitrogen FOXP3 antibody (eBioscience, 14-7979) was used in immunohistochemistry on human samples at 1:50 (fig 2). PLoS ONE (2008) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; tbl 1
In order to assess the regulatory function of human CD25+CD4+ T cells at various stages of maturity, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (tbl 1). Clin Dev Immunol (2008) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 4a
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 4a). Blood (2008) ncbi
rat monoclonal (PCH101)
  • western blot; human; 2 ug/ml
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in western blot on human samples at 2 ug/ml. Cancer Res (2008) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . Cancer Res (2008) ncbi
rat monoclonal (PCH101)
  • flow cytometry; African green monkey
In order to describe the in vitro effects of 5-(4-phenoxybutoxy)psoralen on T cells and its toxicity and pharmacokinetics in rhesus macaques, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on African green monkey samples . Exp Biol Med (Maywood) (2007) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; fig 4
  • immunohistochemistry; human; fig 6
In order to describe retinoids as positive regulatory factors for generating gut-homing FoxP3+ T cells in both humans and mice, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 4) and in immunohistochemistry on human samples (fig 6). J Immunol (2007) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 9A
In order to propose a model in which the gamma chain cytokines IL-2, IL-4, IL-7, and IL-15 maintain the optimal regulatory function of human CD4+ CD25+ T cells in a PI3K-dependent manner, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 9A). Int Immunol (2007) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to observe a female patient with a polyautoimmune autoimmune enteropathy syndrome resembling a mild form of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . Gastroenterology (2007) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 5
In order to determine the expression of CD39 in mouse and human T cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 5). Blood (2007) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to determine the presence and functional characteristics of T regulatory cells in colonic lymphoid tissues in patients with ulcerative colitis, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . Inflamm Bowel Dis (2007) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - frozen section; human
  • flow cytometry; human
In order to report the expression of chemokine receptors on FOXP3+ T cells, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - frozen section on human samples and in flow cytometry on human samples . J Immunol (2006) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to report the expression of chemokine receptors on FOXP3+ T cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . J Immunol (2006) ncbi
Abcam
mouse monoclonal (mAbcam 22510)
  • immunohistochemistry - paraffin section; mouse; 1:100; loading ...; fig 1g
Abcam FOXP3 antibody (Abcam, 22510) was used in immunohistochemistry - paraffin section on mouse samples at 1:100 (fig 1g). Front Med (Lausanne) (2022) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; mouse; loading ...; fig 3d
Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry on mouse samples (fig 3d). Oncoimmunology (2022) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig s10a
Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig s10a). Oncoimmunology (2022) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 4e
Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 4e). EBioMedicine (2022) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:100; fig 4b
Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry on human samples at 1:100 (fig 4b). Cancers (Basel) (2022) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:300; loading ...; tbl 3
Abcam FOXP3 antibody (Abcam, Ab20034) was used in immunohistochemistry - paraffin section on human samples at 1:300 (tbl 3). J Cell Mol Med (2022) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:500; loading ...; fig 1d, 1e
Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry - paraffin section on human samples at 1:500 (fig 1d, 1e). Onco Targets Ther (2021) ncbi
domestic rabbit monoclonal (EPR22102-37)
  • western blot; human; 1:50; loading ...; fig 4h
Abcam FOXP3 antibody (Abcam, ab215206) was used in western blot on human samples at 1:50 (fig 4h). J Cell Mol Med (2021) ncbi
mouse monoclonal (3G3)
  • flow cytometry; mouse; fig s3d
Abcam FOXP3 antibody (Abcam, ab210232) was used in flow cytometry on mouse samples (fig s3d). Mol Cancer (2021) ncbi
domestic rabbit monoclonal (EPR22102-37)
  • immunohistochemistry; mouse; 1:500; fig 5b
Abcam FOXP3 antibody (Abcam, ab215206) was used in immunohistochemistry on mouse samples at 1:500 (fig 5b). Vaccines (Basel) (2021) ncbi
domestic rabbit monoclonal (EPR22102-37)
  • immunohistochemistry; mouse; 1:200; fig 2f
  • western blot; mouse; 1:1000; loading ...; fig 7b
Abcam FOXP3 antibody (Abcam, ab215206) was used in immunohistochemistry on mouse samples at 1:200 (fig 2f) and in western blot on mouse samples at 1:1000 (fig 7b). Cell Death Discov (2021) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; loading ...; fig s4
Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry on human samples (fig s4). Sci Rep (2021) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:200; loading ...; fig s2z
Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry on human samples at 1:200 (fig s2z). Neuropathol Appl Neurobiol (2021) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:100; loading ...; fig 1
Abcam FOXP3 antibody (Abcam, 236/E7) was used in immunohistochemistry on human samples at 1:100 (fig 1). Mol Clin Oncol (2021) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:50; fig 1f
Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry on human samples at 1:50 (fig 1f). BMC Cancer (2021) ncbi
mouse monoclonal (mAbcam 22510)
  • immunohistochemistry; human; 1:50; loading ...
Abcam FOXP3 antibody (Abcam, 22510) was used in immunohistochemistry on human samples at 1:50. Ann Hematol (2021) ncbi
mouse monoclonal (mAbcam 22510)
  • immunohistochemistry - paraffin section; human; 1:50; loading ...; fig 7a
Abcam FOXP3 antibody (Abcam, mAbcam22510) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 7a). Arthritis Res Ther (2020) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 1c
Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1c). Breast Cancer Res (2020) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:50; loading ...; fig 3c
Abcam FOXP3 antibody (Abcam, ab2034) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 3c). Front Immunol (2019) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:400; loading ...; fig 3a
Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples at 1:400 (fig 3a). Cancer Sci (2020) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - frozen section; human; 1:100; loading ...; fig 1f
Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - frozen section on human samples at 1:100 (fig 1f). J Invest Dermatol (2019) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; fig 1a
Abcam FOXP3 antibody (Abcam, 20034) was used in immunohistochemistry - paraffin section on human samples (fig 1a). Sci Rep (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 2k
Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2k). Arch Dermatol Res (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; mouse; loading ...; fig s3b
Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry on mouse samples (fig s3b). FASEB J (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; loading ...; fig 2c
In order to investigate the immune composition of tumor microenvironment in hepatocellular carcinoma, Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples (fig 2c). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (mAbcam 22510)
  • immunohistochemistry - paraffin section; human; loading ...; tbl 1
In order to investigate infiltrating T cells in liver cancer through single-cell sequencing, Abcam FOXP3 antibody (Abcam, ab22510) was used in immunohistochemistry - paraffin section on human samples (tbl 1). Cell (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:50; loading ...; fig 2c
In order to investigate origin of tumor-infiltrating T regulatory cells in breast cancer samples, Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry on human samples at 1:50 (fig 2c). Cell Res (2017) ncbi
mouse monoclonal (236a/E7)
  • western blot; human; loading ...; fig 3D
Abcam FOXP3 antibody (Abcam, ab20034) was used in western blot on human samples (fig 3D). Int J Mol Sci (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - frozen section; human; loading ...; fig 4b
In order to observe that the use of chimeric antigen receptor technology is a clinically applicable refinement of regulatory T cell therapy for organ transplantation, Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - frozen section on human samples (fig 4b). Am J Transplant (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; fig 1c
In order to profile the infiltration levels of immune cell populations in 19 cancer types, Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry on human samples (fig 1c). Genome Biol (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 2c
In order to investigate the role of PD-L1 and T-cell infiltration in metastatic high-grade osteosarcoma, Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2c). Cancer Immunol Immunother (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 20 ug/ml; loading ...; fig 3a
Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry - paraffin section on human samples at 20 ug/ml (fig 3a). J Immunol Res (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1
Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples (fig 1). Cancer Sci (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; loading ...; tbl 3
In order to characterize cases of recurrent panniculitis in children with lipoatrophy, Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples (tbl 3). J Eur Acad Dermatol Venereol (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; fig 2b
In order to report that patients with PTEN mutations experience autoimmunity and lymphoid hyperplasia, Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples (fig 2b). J Allergy Clin Immunol (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; mouse; fig 6b
In order to utilize humanized major histocompatibility class I- and class II-deficient NOG mice to assess the antitumor effect of an anti-programmed death-1 antibody, Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry on mouse samples (fig 6b). Clin Cancer Res (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; mouse; 1:500; fig 3
Abcam FOXP3 antibody (abcam, ab20034) was used in immunohistochemistry - paraffin section on mouse samples at 1:500 (fig 3). Mol Med Rep (2016) ncbi
monoclonal
  • immunohistochemistry - paraffin section; human; 1:50; fig 1
Abcam FOXP3 antibody (abcam, ab450) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 1). Oncol Lett (2016) ncbi
mouse monoclonal (mAbcam 22510)
  • immunohistochemistry - paraffin section; human; fig 1F
Abcam FOXP3 antibody (Abcam, ab22510) was used in immunohistochemistry - paraffin section on human samples (fig 1F). PLoS ONE (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1
In order to study the role of neuropathy and imbalanced Foxp3/IL-17 in bone marrow microenvironment of acute myeloid leukemia patients, Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry - paraffin section on human samples (fig 1). Oncotarget (2016) ncbi
monoclonal
  • immunohistochemistry - paraffin section; human; fig 1
In order to assess the correlation with the immune infiltration in breast cancer due to the presence of HMGB1and LC3B puncta expression in malignant cells, Abcam FOXP3 antibody (Abcam, ab450) was used in immunohistochemistry - paraffin section on human samples (fig 1). Autophagy (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:100; fig 3
Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 3). Mod Pathol (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1
In order to correlate tumor infiltrating lymphocyte types with clinical outcomes in patients with head and neck squamous cell carcinoma, Abcam FOXP3 antibody (Abcam, Ab20034) was used in immunohistochemistry - paraffin section on human samples (fig 1). Head Neck (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:50; tbl 2
In order to evaluate the reliance on EBV or NF-kappaB signaling instead of B-cell receptor signaling in regards to complete phenotypic characterization of PTLD, Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry on human samples at 1:50 (tbl 2). Hematol Oncol (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:100
In order to assess how proportional balance of tumor associated macrophages and tumor infiltrating lymphocytes in microsatellite-unstable gastric carcinoma is a prognostic indicator of M2 macrophages, Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples at 1:100. PLoS ONE (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; loading ...; fig 2
Abcam FOXP3 antibody (Abcam, AB20034) was used in immunohistochemistry - paraffin section on human samples (fig 2). J Immunother Cancer (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human
In order to examine the histopathological patterns and their associations with clinical characteristics in Chinese patients with nasal inverted papilloma, Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples . Laryngoscope (2016) ncbi
monoclonal
  • immunohistochemistry - paraffin section; human; fig 3
In order to examine the immune responses in patients with esophageal carcinomas treated by neo-adjuvant radiochemotherapy, Abcam FOXP3 antibody (Abcam, ab450) was used in immunohistochemistry - paraffin section on human samples (fig 3). Oncotarget (2015) ncbi
mouse monoclonal (mAbcam 22510)
  • immunohistochemistry - paraffin section; human; 20 ug/ml; loading ...; fig 3b
  • western blot; human; loading ...; fig 3f
Abcam FOXP3 antibody (abcam, ab22510) was used in immunohistochemistry - paraffin section on human samples at 20 ug/ml (fig 3b) and in western blot on human samples (fig 3f). PLoS ONE (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; fig 5
In order to determine the expression and function of HLA-G, HLA-G-regulatory microRNAs and the immune cell infiltration in renal cell carcinoma samples, Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry on human samples (fig 5). Oncoimmunology (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human
Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry - paraffin section on human samples . Cancer Immunol Immunother (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:800
Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples at 1:800. J Dermatol Sci (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; fig St1A
Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry - paraffin section on human samples (fig St1A). Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human
In order to study the role of lymph node in the early rectal cancer, Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry on human samples . Dis Markers (2014) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:60
Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples at 1:60. World J Gastroenterol (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:180; fig 4
In order to characterize location and tumor infiltration patterns as key prognostic factors when analyzing CD8+ T-cells and FoxP3+ T-regulatory cells in ovarian carcinoma, Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry - paraffin section on human samples at 1:180 (fig 4). PLoS ONE (2014) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; fig 1
Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples (fig 1). Cancer Discov (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; loading ...; fig 1c
Abcam FOXP3 antibody (Abcam, ab20034) was used in immunohistochemistry on human samples (fig 1c). Liver Int (2015) ncbi
mouse monoclonal (mAbcam 22510)
  • western blot; human; loading ...; fig 1a
Abcam FOXP3 antibody (Abcam, ab22510) was used in western blot on human samples (fig 1a). Liver Int (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:100
Abcam FOXP3 antibody (Abcam, 236 A/E7) was used in immunohistochemistry - paraffin section on human samples at 1:100. Br J Dermatol (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:100
Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry on human samples at 1:100. PLoS Pathog (2014) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human
Abcam FOXP3 antibody (Abcam, 236A/E7) was used in immunohistochemistry - paraffin section on human samples . Cancer (2011) ncbi
BioLegend
mouse monoclonal (150D)
  • flow cytometry; rat; loading ...; fig 10a
BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on rat samples (fig 10a). PLoS ONE (2022) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; loading ...; fig s5e
BioLegend FOXP3 antibody (Biolegend, 150D) was used in flow cytometry on mouse samples (fig s5e). Leukemia (2022) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; fig 2f
BioLegend FOXP3 antibody (Biolegend, 150D) was used in flow cytometry on mouse samples (fig 2f). Theranostics (2022) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; fig s5f
BioLegend FOXP3 antibody (BioLegend, 320124) was used in flow cytometry on human samples (fig s5f). Sci Adv (2022) ncbi
mouse monoclonal (150D)
  • flow cytometry; human; loading ...; fig 1c
BioLegend FOXP3 antibody (Biolegend, 150D) was used in flow cytometry on human samples (fig 1c). Oncoimmunology (2022) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; loading ...; fig 2i, 6d, 6e
BioLegend FOXP3 antibody (BioLegend, 320008) was used in flow cytometry on mouse samples (fig 2i, 6d, 6e). Mol Ther Nucleic Acids (2022) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 1e
BioLegend FOXP3 antibody (BioLegend, 320108) was used in flow cytometry on human samples (fig 1e). Mol Ther Nucleic Acids (2022) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; 1:100; loading ...; fig 6b
BioLegend FOXP3 antibody (Biolegend, 320115) was used in flow cytometry on human samples at 1:100 (fig 6b). Nat Nanotechnol (2022) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; fig 5g
BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on mouse samples (fig 5g). Sci Adv (2021) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; loading ...; fig 6b
BioLegend FOXP3 antibody (BioLegend, 320 208) was used in flow cytometry on human samples (fig 6b). Adv Sci (Weinh) (2021) ncbi
mouse monoclonal (259D)
  • immunohistochemistry - paraffin section; human; 1:50; loading ...; fig s1a
BioLegend FOXP3 antibody (Biolegend, 320201) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig s1a). Front Cell Dev Biol (2021) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; 1:100; loading ...; fig 1a
BioLegend FOXP3 antibody (Biolegend, 150D) was used in flow cytometry on mouse samples at 1:100 (fig 1a). Nat Commun (2021) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; loading ...; fig 3a
BioLegend FOXP3 antibody (BioLegend, 320214) was used in flow cytometry on human samples (fig 3a). Immunity (2021) ncbi
mouse monoclonal (206D)
  • immunohistochemistry; mouse; loading ...; fig s1l
BioLegend FOXP3 antibody (BioLegend, 320114) was used in immunohistochemistry on mouse samples (fig s1l). Cell (2020) ncbi
mouse monoclonal (206D)
  • immunohistochemistry - paraffin section; human; loading ...; fig 3
BioLegend FOXP3 antibody (BioLegend, 206D) was used in immunohistochemistry - paraffin section on human samples (fig 3). Front Immunol (2020) ncbi
mouse monoclonal (206D)
  • immunohistochemistry - paraffin section; human; 1:50; loading ...; fig 2e
  • immunohistochemistry; human; 1:50; loading ...; fig 2f
BioLegend FOXP3 antibody (Biolegend, 320102) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 2e) and in immunohistochemistry on human samples at 1:50 (fig 2f). Nature (2020) ncbi
mouse monoclonal (150D)
  • flow cytometry; human; 1:100; loading ...; fig 7a
BioLegend FOXP3 antibody (Biolegend, 320012) was used in flow cytometry on human samples at 1:100 (fig 7a). elife (2019) ncbi
mouse monoclonal (150D)
  • flow cytometry; human; loading ...; fig 4f
BioLegend FOXP3 antibody (Biolegend, 320014) was used in flow cytometry on human samples (fig 4f). Cell Mol Gastroenterol Hepatol (2020) ncbi
mouse monoclonal (206D)
  • immunohistochemistry; human; loading ...; fig 3c
BioLegend FOXP3 antibody (BioLegend, 320102) was used in immunohistochemistry on human samples (fig 3c). Cell (2019) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; 1:50; fig 1d
BioLegend FOXP3 antibody (Biolegend, 320213) was used in flow cytometry on human samples at 1:50 (fig 1d). Nat Commun (2019) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; 1:500; loading ...; fig e2f
BioLegend FOXP3 antibody (Biolegend, 320008) was used in flow cytometry on mouse samples at 1:500 (fig e2f). Nature (2019) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; loading ...; fig s8c
BioLegend FOXP3 antibody (BioLegend, 259D) was used in flow cytometry on human samples (fig s8c). Nat Immunol (2019) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; 1:40; loading ...; fig 6s1
BioLegend FOXP3 antibody (Biolegend, 320007) was used in flow cytometry on mouse samples at 1:40 (fig 6s1). elife (2019) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; loading ...; fig 3b
BioLegend FOXP3 antibody (Biolegend, 150D) was used in flow cytometry on mouse samples (fig 3b). Int J Cancer (2019) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; loading ...; fig 5a
BioLegend FOXP3 antibody (BioLegend, 259D) was used in flow cytometry on human samples (fig 5a). Front Immunol (2018) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; 1:10; loading ...; fig 2a
BioLegend FOXP3 antibody (Biolegend, 320212) was used in flow cytometry on human samples at 1:10 (fig 2a). Nat Med (2019) ncbi
mouse monoclonal (259D)
  • other; human; loading ...; fig 2a
BioLegend FOXP3 antibody (BioLegend, 320208) was used in other on human samples (fig 2a). J Clin Invest (2018) ncbi
mouse monoclonal (150D)
  • flow cytometry; rhesus macaque; loading ...; fig 2g
BioLegend FOXP3 antibody (Biolegend, 150D) was used in flow cytometry on rhesus macaque samples (fig 2g). J Virol (2019) ncbi
mouse monoclonal (150D)
  • flow cytometry; human; loading ...; fig 3c
BioLegend FOXP3 antibody (Biolegend, 320013) was used in flow cytometry on human samples (fig 3c). Biosci Rep (2018) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 1
BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 1). Am J Trop Med Hyg (2018) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; loading ...; fig s2a
BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on mouse samples (fig s2a). J Clin Invest (2018) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 3b
  • immunohistochemistry; human; loading ...; fig 3a
BioLegend FOXP3 antibody (Biolegend, 206D) was used in flow cytometry on human samples (fig 3b) and in immunohistochemistry on human samples (fig 3a). J Immunol (2018) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 4d
In order to detail MAIT cell responses to various microorganisms and cytokines, BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 4d). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; 1:50; loading ...; fig 5b
BioLegend FOXP3 antibody (Biolegend, 150D) was used in flow cytometry on mouse samples at 1:50 (fig 5b). Nat Commun (2017) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; loading ...; fig 4c
In order to discover that SIRPalpha is highly expressed in human renal cell carcinoma and melanoma, BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on mouse samples (fig 4c). JCI Insight (2017) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 4d
In order to investigate the roles of CD16+ monocytes in T-cell activation and B-cell responses in systemic lupus erythematosus, BioLegend FOXP3 antibody (Biolegend, 320114) was used in flow cytometry on human samples (fig 4d). Front Immunol (2016) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 1b
BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 1b). Cell Death Dis (2016) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 2b
In order to investigate the basis for T regulatory cell accumulation in melanoma, BioLegend FOXP3 antibody (Biolegend, 206D) was used in flow cytometry on human samples (fig 2b). Cancer Res (2016) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; fig s2
BioLegend FOXP3 antibody (Biolegend, 206D) was used in flow cytometry on human samples (fig s2). PLoS Pathog (2016) ncbi
mouse monoclonal (206D)
  • immunohistochemistry - paraffin section; human; 5 ug/ml; loading ...; tbl 2
In order to measure FoxP3 and IL17 expression in patients with oral lichen planus, BioLegend FOXP3 antibody (Biolegend, 320102) was used in immunohistochemistry - paraffin section on human samples at 5 ug/ml (tbl 2). Pathology (2016) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; 1:20; fig st2
BioLegend FOXP3 antibody (Biolegend, 320216) was used in flow cytometry on human samples at 1:20 (fig st2). Nat Commun (2016) ncbi
mouse monoclonal (150D)
  • chromatin immunoprecipitation; mouse; fig 4
In order to study the requisite for the function of regulatory T cells known as phosphatase PP2A, BioLegend FOXP3 antibody (Biolegend, 150D) was used in chromatin immunoprecipitation on mouse samples (fig 4). Nat Immunol (2016) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; fig 5d
BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on mouse samples (fig 5d). Gastroenterology (2016) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 6b
In order to discuss the impact of filaggrin mutations on the development of atopic dermatitis, BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 6b). J Allergy Clin Immunol (2016) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; fig 6
In order to study how a novel multi-drug metronomic chemotherapy can delay tumor growth in mice significantly, BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on mouse samples (fig 6). J Transl Med (2016) ncbi
mouse monoclonal (150D)
  • western blot; mouse; 1:500; fig 4
BioLegend FOXP3 antibody (Biolegend, 150D) was used in western blot on mouse samples at 1:500 (fig 4). PLoS ONE (2015) ncbi
mouse monoclonal (150D)
  • flow cytometry; human
BioLegend FOXP3 antibody (Biolegend, 320014) was used in flow cytometry on human samples . Mol Oncol (2015) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; fig 2
In order to study engineered anti-melanoma vaccines that modulate cytokine priming and silence PD-L1 simultaneously by use of ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy, BioLegend FOXP3 antibody (BioLegend, 320014) was used in flow cytometry on mouse samples (fig 2). Oncoimmunology (2014) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; fig 6
In order to report the phase I trial results of CDX-301, BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 6). Bone Marrow Transplant (2015) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; tbl s1
BioLegend FOXP3 antibody (Biolegend, 206D) was used in flow cytometry on human samples (tbl s1). PLoS ONE (2015) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; fig 6
BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 6). PLoS ONE (2015) ncbi
mouse monoclonal (150D)
  • flow cytometry; human; fig 5
BioLegend FOXP3 antibody (Biolegend, 150D) was used in flow cytometry on human samples (fig 5). J Cell Mol Med (2015) ncbi
mouse monoclonal (206D)
  • immunohistochemistry; human; fig 2
BioLegend FOXP3 antibody (320102, 320102) was used in immunohistochemistry on human samples (fig 2). Clin Cancer Res (2015) ncbi
mouse monoclonal (259D)
  • flow cytometry; mouse; fig 8
BioLegend FOXP3 antibody (BioLegend, 320212) was used in flow cytometry on mouse samples (fig 8). J Immunol (2015) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 1
In order to investigate the role of granzyme B in T regulatory cell resistance, BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 1). J Immunol (2015) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse
BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on mouse samples . J Immunol (2014) ncbi
mouse monoclonal (150D)
  • flow cytometry; rat; fig 7
BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on rat samples (fig 7). Eur J Immunol (2015) ncbi
mouse monoclonal (206D)
BioLegend FOXP3 antibody (Biolegend, 206D) was used . PLoS ONE (2014) ncbi
mouse monoclonal (206D)
BioLegend FOXP3 antibody (BioLegend, 320102) was used . Cancer Immunol Res (2014) ncbi
mouse monoclonal (150D)
In order to study the modulation of CD4 T-cell senescence and cytokine production and the roles played by Menin and Bach2, BioLegend FOXP3 antibody (BioLegend, 150D) was used . Nat Commun (2014) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse
BioLegend FOXP3 antibody (Biolegend, 320013) was used in flow cytometry on mouse samples . Exp Parasitol (2014) ncbi
mouse monoclonal (150D)
  • immunocytochemistry; human; 1:50
BioLegend FOXP3 antibody (BioLegend, 150D) was used in immunocytochemistry on human samples at 1:50. Nephrology (Carlton) (2014) ncbi
Santa Cruz Biotechnology
mouse monoclonal (2A11G9)
  • western blot; human; loading ...; fig 5f
Santa Cruz Biotechnology FOXP3 antibody (Santa Cruz, SC-53876) was used in western blot on human samples (fig 5f). J Immunother Cancer (2022) ncbi
mouse monoclonal (2A11G9)
  • immunohistochemistry - paraffin section; mouse; 1:50; loading ...; fig s6c
Santa Cruz Biotechnology FOXP3 antibody (Santa, sc-53876) was used in immunohistochemistry - paraffin section on mouse samples at 1:50 (fig s6c). Theranostics (2021) ncbi
mouse monoclonal (2A11G9)
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 4
  • western blot; mouse; 1:500; loading ...; fig 6a, 6b
Santa Cruz Biotechnology FOXP3 antibody (Santa Cruz, sc-53,876) was used in immunohistochemistry - paraffin section on mouse samples (fig 4) and in western blot on mouse samples at 1:500 (fig 6a, 6b). BMC Nephrol (2019) ncbi
mouse monoclonal (F-9)
  • immunohistochemistry - paraffin section; mouse; tbl 1
In order to characterize histomorphometric tumors by induction of colorectal cancer in mice, Santa Cruz Biotechnology FOXP3 antibody (Santa Cruz, sc166212) was used in immunohistochemistry - paraffin section on mouse samples (tbl 1). Methods Mol Biol (2015) ncbi
R&D Systems
domestic rabbit monoclonal (1054C)
  • immunohistochemistry; human; 1:100; loading ...; fig s2d
R&D Systems FOXP3 antibody (R&D System, MAB8214) was used in immunohistochemistry on human samples at 1:100 (fig s2d). Adv Sci (Weinh) (2021) ncbi
Miltenyi Biotec
human monoclonal (REA788)
  • immunocytochemistry; mouse; loading ...; fig s1l
Miltenyi Biotec FOXP3 antibody (Miltenyi Biotec, 130-111-601) was used in immunocytochemistry on mouse samples (fig s1l). Cell (2020) ncbi
Novus Biologicals
domestic rabbit polyclonal
  • immunohistochemistry - frozen section; mouse; 1:200; loading ...; fig 3f
Novus Biologicals FOXP3 antibody (Novus, NB100-39002) was used in immunohistochemistry - frozen section on mouse samples at 1:200 (fig 3f). Aging (Albany NY) (2019) ncbi
domestic rabbit polyclonal
In order to use personalized immunotherapy to target individual tumor-specific mutations in patients, Novus Biologicals FOXP3 antibody (Novus Biologicals, NB100-39002) was used . Nature (2015) ncbi
OriGene
domestic rabbit polyclonal (polyclonal)
  • western blot; human; loading ...; fig 1i
In order to show reverse post-translational regulation of HIF-1alpha by Foxp3, OriGene FOXP3 antibody (Origene, TA319911) was used in western blot on human samples (fig 1i). Oncotarget (2016) ncbi
Cell Signaling Technology
domestic rabbit monoclonal (D2W8E)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 4a
Cell Signaling Technology FOXP3 antibody (Cell Signaling, 98377) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 4a). J Immunother Cancer (2021) ncbi
domestic rabbit monoclonal (D2W8E)
  • immunohistochemistry - paraffin section; human; 1:400; loading ...; fig 6a
Cell Signaling Technology FOXP3 antibody (Cell Signaling, 98377S) was used in immunohistochemistry - paraffin section on human samples at 1:400 (fig 6a). Nat Commun (2019) ncbi
domestic rabbit monoclonal (D2W8E)
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 1c
Cell Signaling Technology FOXP3 antibody (Cell Signaling, 98377S) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 1c). J Immunother Cancer (2019) ncbi
domestic rabbit monoclonal (D2W8E)
  • immunocytochemistry; human; 1:100; fig s6c
In order to elucidate the clinical importance of IDO1 protein in hormone receptor-positive breast cancer, Cell Signaling Technology FOXP3 antibody (Cell Signaling, D2W8E) was used in immunocytochemistry on human samples at 1:100 (fig s6c). J Immunother Cancer (2017) ncbi
Tonbo Biosciences
mouse monoclonal (3G3)
  • flow cytometry; mouse; 1:100; loading ...; fig 5a
Tonbo Biosciences FOXP3 antibody (Tonbo, 3G3) was used in flow cytometry on mouse samples at 1:100 (fig 5a). J Immunol Res (2021) ncbi
mouse monoclonal (3G3)
  • flow cytometry; mouse; loading ...; fig 4b
Tonbo Biosciences FOXP3 antibody (Tonbo, 3G3) was used in flow cytometry on mouse samples (fig 4b). Nutrients (2018) ncbi
mouse monoclonal (3G3)
  • flow cytometry; mouse; loading ...; fig 2e
In order to determine the role of CD6 in T cells using knock out mice, Tonbo Biosciences FOXP3 antibody (TONBO Bioscience, 3G3) was used in flow cytometry on mouse samples (fig 2e). J Exp Med (2016) ncbi
BD Biosciences
mouse monoclonal (236a/E7)
  • flow cytometry; human; 1:30; loading ...; fig 2g
BD Biosciences FOXP3 antibody (BD, 561493) was used in flow cytometry on human samples at 1:30 (fig 2g). Nat Commun (2022) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig 8b
BD Biosciences FOXP3 antibody (BD Biosciences, 259D/C7) was used in flow cytometry on human samples (fig 8b). J Clin Invest (2022) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; mouse; loading ...; fig 3h
BD Biosciences FOXP3 antibody (BD Biosciences, 560852) was used in flow cytometry on mouse samples (fig 3h). Front Physiol (2021) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 2i
BD Biosciences FOXP3 antibody (BD Biosciences, 561184) was used in flow cytometry on human samples (fig 2i). Am J Respir Crit Care Med (2021) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...
BD Biosciences FOXP3 antibody (BD, 560047) was used in flow cytometry on human samples . Cell (2021) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig 4a-4d
BD Biosciences FOXP3 antibody (BD Biosciences, 560045) was used in flow cytometry on human samples (fig 4a-4d). elife (2020) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig s1c
BD Biosciences FOXP3 antibody (Becton Dickinson, 562421) was used in flow cytometry on human samples (fig s1c). Cell (2020) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig 7k
BD Biosciences FOXP3 antibody (BD, 259D/C7) was used in flow cytometry on human samples (fig 7k). J Exp Med (2020) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig s1
BD Biosciences FOXP3 antibody (BD Biosciences, 259D/C7) was used in flow cytometry on human samples (fig s1). J Exp Med (2019) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig 3a
BD Biosciences FOXP3 antibody (BD, 259D/C7) was used in flow cytometry on human samples (fig 3a). Front Immunol (2019) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig 1c
BD Biosciences FOXP3 antibody (BD Biosciences, 259D/C7) was used in flow cytometry on human samples (fig 1c). Leukemia (2019) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; fig 1b
BD Biosciences FOXP3 antibody (BD Biosciences, 259D/C7) was used in flow cytometry on human samples (fig 1b). J Exp Med (2018) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig s2d
In order to characterize CD8 T cells isolated patients with stage IV melanoma before and after treatment with pembrolizumab, BD Biosciences FOXP3 antibody (BD, 259D/C7) was used in flow cytometry on human samples (fig s2d). Nature (2017) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
In order to characterize activated T cells in joint tissue from patients with rheumatoid arthritis, BD Biosciences FOXP3 antibody (BD BIOSCIENCES, 236A/E7) was used in flow cytometry on human samples . Nature (2017) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig s1c
In order to describe complete autosomal recessive IL-17RA deficiency in patients with chronic mucocutaneous candidiasis, BD Biosciences FOXP3 antibody (BD Biosciences, 259D/C7) was used in flow cytometry on human samples (fig s1c). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 1
In order to study the role of PD-1 and Tim-3 crosstalk in the regulation of antitumor T cell responses, BD Biosciences FOXP3 antibody (BD, 561493) was used in flow cytometry on human samples (fig 1). Oncoimmunology (2016) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig s7
BD Biosciences FOXP3 antibody (BD Biosciences, 259D) was used in flow cytometry on human samples (fig s7). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; tbl 3
BD Biosciences FOXP3 antibody (BD Pharmingen, 259D/C7) was used in flow cytometry on human samples (tbl 3). Brain Behav (2016) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...
In order to identify RLTPR in patients and determine the effects of these mutations on CD4 positive T cells, BD Biosciences FOXP3 antibody (BD, 259D/C7) was used in flow cytometry on human samples . J Exp Med (2016) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; 1:100; fig 4
In order to determine mediation of differentiation and cisplatin chemotherapy resistance by biased expression of the FOXP3delta3 isoform in aggressive bladder cancer, BD Biosciences FOXP3 antibody (BD Biosciences, 560045) was used in flow cytometry on human samples at 1:100 (fig 4). Clin Cancer Res (2016) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; fig st1
In order to find cell-surface markers specific to human neutrophils, BD Biosciences FOXP3 antibody (BD, 560046) was used in flow cytometry on human samples (fig st1). Exp Cell Res (2016) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig 4b
In order to study heat-shock protein 70 in non-small cell lung cancer cells, BD Biosciences FOXP3 antibody (BD, 560046) was used in flow cytometry on human samples (fig 4b). Front Immunol (2015) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; 1:25; tbl 1
BD Biosciences FOXP3 antibody (BD Horizon, 562421) was used in flow cytometry on human samples at 1:25 (tbl 1). PLoS ONE (2015) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig 2b
BD Biosciences FOXP3 antibody (BD PharMingen, 560046) was used in flow cytometry on human samples (fig 2b). PLoS ONE (2015) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; fig s1
BD Biosciences FOXP3 antibody (BD Pharmingen, 561181) was used in flow cytometry on human samples (fig s1). Stem Cell Reports (2015) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 1b,1c,1e,1f
In order to look at patterns of S. Typhi-specific modulation of the homing potential of circulating Treg in patients with typhoid compared to healthy individuals, BD Biosciences FOXP3 antibody (BD, 561493) was used in flow cytometry on human samples (fig 1b,1c,1e,1f). PLoS Pathog (2015) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; fig 2
BD Biosciences FOXP3 antibody (BD Biosciences, 236A/E7) was used in flow cytometry on human samples (fig 2). J Autoimmun (2015) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; fig 1
BD Biosciences FOXP3 antibody (BD Biosciences, 259D) was used in flow cytometry on human samples (fig 1). Diabetes (2015) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig 1g
In order to determine the role of IL-10 produced by T regulatory cells in patients with immune thrombocytopenia, BD Biosciences FOXP3 antibody (BD Bioscience, 560459) was used in flow cytometry on human samples (fig 1g). Immunol Res (2015) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human
BD Biosciences FOXP3 antibody (BD Biosciences, 259D/C7) was used in flow cytometry on human samples . J Immunol (2015) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human
BD Biosciences FOXP3 antibody (BD, 259D/C7) was used in flow cytometry on human samples . J Immunol (2015) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human
BD Biosciences FOXP3 antibody (BD Biosciences, 259D/C7) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; fig 1
BD Biosciences FOXP3 antibody (BD Biosciences, 259D/C7) was used in flow cytometry on human samples (fig 1). Cancer Discov (2015) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human; loading ...; fig 1b
In order to show that latency-associated peptide and glycoprotein A repetitions predominant identify human antigen-specific T regulatory cells, BD Biosciences FOXP3 antibody (BD, 259D/C7) was used in flow cytometry on human samples (fig 1b). Eur J Immunol (2014) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human
BD Biosciences FOXP3 antibody (BD Pharmingen, 259D/C7) was used in flow cytometry on human samples . Immunol Cell Biol (2014) ncbi
mouse monoclonal (259D/C7)
  • flow cytometry; human
BD Biosciences FOXP3 antibody (BD Biosciences, 259D/C7) was used in flow cytometry on human samples . PLoS Pathog (2014) ncbi
Articles Reviewed
  1. Ravindranathan S, Passang T, Li J, Wang S, Dhamsania R, Ware M, et al. Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. Nat Commun. 2022;13:6418 pubmed publisher
  2. Bath N, Verhoven B, Wilson N, Zeng W, Zhong W, Coons L, et al. APRIL/BLyS deficient rats prevent donor specific antibody (DSA) production and cell proliferation in rodent kidney transplant model. PLoS ONE. 2022;17:e0275564 pubmed publisher
  3. Ni H, Zhang H, Li L, Huang H, Guo H, Zhang L, et al. T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer. J Immunother Cancer. 2022;10: pubmed publisher
  4. Lee A, Pingali S, Pinilla Ibarz J, Atchison M, Koumenis C, Argon Y, et al. Loss of AID exacerbates the malignant progression of CLL. Leukemia. 2022;36:2430-2442 pubmed publisher
  5. Coy S, Wang S, Stopka S, Lin J, Yapp C, Ritch C, et al. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma. Nat Commun. 2022;13:4814 pubmed publisher
  6. Wu B, Song M, Dong Q, Xiang G, Li J, Ma X, et al. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer. Theranostics. 2022;12:5086-5102 pubmed publisher
  7. Son M, Park I, Kim S, Ma H, Kim J, Kim T, et al. Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function. Front Immunol. 2022;13:870817 pubmed publisher
  8. Wang Y, Feng R, Cheng G, Huang B, Tian J, Gan Y, et al. Low Dose Interleukin-2 Ameliorates Sjögren's Syndrome in a Murine Model. Front Med (Lausanne). 2022;9:887354 pubmed publisher
  9. Qin L, Wang L, Zhang J, Zhou H, Yang Z, Wang Y, et al. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer. Sci Adv. 2022;8:eabn3774 pubmed publisher
  10. Pan C, Wu Q, Wang S, Mei Z, Zhang L, Gao X, et al. Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma. Oncoimmunology. 2022;11:2073010 pubmed publisher
  11. Melese E, Franks E, Cederberg R, Harbourne B, Shi R, Wadsworth B, et al. CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development. Oncoimmunology. 2022;11:2010905 pubmed publisher
  12. Tu J, Han D, Fang Y, Jiang H, Tan X, Xu Z, et al. MicroRNA-10b promotes arthritis development by disrupting CD4+ T cell subtypes. Mol Ther Nucleic Acids. 2022;27:733-750 pubmed publisher
  13. Yang J, Zhang Q, Wang J, Lou Y, Hong Z, Wei S, et al. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. EBioMedicine. 2022;78:103958 pubmed publisher
  14. Ploeger C, Schreck J, Huth T, Fraas A, Albrecht T, Charbel A, et al. STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. Cancers (Basel). 2022;14: pubmed publisher
  15. Besnard M, S xe9 razin C, Ossart J, Moreau A, Vimond N, Flippe L, et al. Anti-CD45RC antibody immunotherapy prevents and treats experimental autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. J Clin Invest. 2022;132: pubmed publisher
  16. Pulkka O, Viisanen L, Tynninen O, Laaksonen M, Reichardt P, Reichardt A, et al. Fibrinogen-like protein 2 in gastrointestinal stromal tumour. J Cell Mol Med. 2022;26:1083-1094 pubmed publisher
  17. Liu Y, Wang L, Song Q, Ali M, Crowe W, Kucera G, et al. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nat Nanotechnol. 2022;17:206-216 pubmed publisher
  18. Ma X, Gao Y, Chen Y, Liu J, Yang C, Bao C, et al. M2-Type Macrophages Induce Tregs Generation by Activating the TGF-β/Smad Signalling Pathway to Promote Colorectal Cancer Development. Onco Targets Ther. 2021;14:5391-5402 pubmed publisher
  19. Ni Y, Hu B, Wu G, Shao Z, Zheng Y, Zhang R, et al. Interruption of neutrophil extracellular traps formation dictates host defense and tubular HOXA5 stability to augment efficacy of anti-Fn14 therapy against septic AKI. Theranostics. 2021;11:9431-9451 pubmed publisher
  20. Horiuchi S, Wu H, Liu W, Schmitt N, Provot J, Liu Y, et al. Tox2 is required for the maintenance of GC TFH cells and the generation of memory TFH cells. Sci Adv. 2021;7:eabj1249 pubmed publisher
  21. Zou J, Pei X, Xing D, Wu X, Chen S. LINC00261 elevation inhibits angiogenesis and cell cycle progression of pancreatic cancer cells by upregulating SCP2 via targeting FOXP3. J Cell Mol Med. 2021;25:9826-9836 pubmed publisher
  22. Liu Z, Wang T, She Y, Wu K, Gu S, Li L, et al. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. Mol Cancer. 2021;20:105 pubmed publisher
  23. Xu M, Zheng X, Wang D, Fu X, Xing Y, Liu Y, et al. Blockage of C-X-C Motif Chemokine Receptor 2 (CXCR2) Suppressed Uric Acid (UA)-Induced Cardiac Remodeling. Front Physiol. 2021;12:700338 pubmed publisher
  24. Guo L, Xie H, Zhang Z, Wang Z, Peng S, Niu Y, et al. Fusion Protein Vaccine Based on Ag85B and STEAP1 Induces a Protective Immune Response against Prostate Cancer. Vaccines (Basel). 2021;9: pubmed publisher
  25. Kim G, Kim W, Lim S, Lee H, Koo J, Nam K, et al. In Vivo Induction of Regulatory T Cells Via CTLA-4 Signaling Peptide to Control Autoimmune Encephalomyelitis and Prevent Disease Relapse. Adv Sci (Weinh). 2021;8:2004973 pubmed publisher
  26. Lu J, Wang W, Li P, Wang X, Gao C, Zhang B, et al. MiR-146a regulates regulatory T cells to suppress heart transplant rejection in mice. Cell Death Discov. 2021;7:165 pubmed publisher
  27. Wu Q, Tian A, Li B, Leduc M, Forveille S, Hamley P, et al. IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms. J Immunother Cancer. 2021;9: pubmed publisher
  28. Zhang J, Qi J, Wei H, Lei Y, Yu H, Liu N, et al. TGFβ1 in Cancer-Associated Fibroblasts Is Associated With Progression and Radiosensitivity in Small-Cell Lung Cancer. Front Cell Dev Biol. 2021;9:667645 pubmed publisher
  29. Lomphithak T, Akara Amornthum P, Murakami K, Hashimoto M, Usubuchi H, Iwabuchi E, et al. Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma. Sci Rep. 2021;11:11743 pubmed publisher
  30. Zimmer T, Broekaart D, Luinenburg M, Mijnsbergen C, Anink J, Sim N, et al. Balloon cells promote immune system activation in focal cortical dysplasia type 2b. Neuropathol Appl Neurobiol. 2021;47:826-839 pubmed publisher
  31. Amoozgar Z, Kloepper J, Ren J, Tay R, Kazer S, Kiner E, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021;12:2582 pubmed publisher
  32. Lindskrog S, Prip F, Lamy P, Taber A, Groeneveld C, Birkenkamp Demtroder K, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12:2301 pubmed publisher
  33. Harada Y, Kazama S, Morikawa T, Sonoda H, Ishi H, Emoto S, et al. Clinical significance of CD8+ and FoxP3+ tumor-infiltrating lymphocytes and MFG-E8 expression in lower rectal cancer with preoperative chemoradiotherapy. Mol Clin Oncol. 2021;14:87 pubmed publisher
  34. Szabo P, Dogra P, Gray J, Wells S, Connors T, Weisberg S, et al. Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. Immunity. 2021;54:797-814.e6 pubmed publisher
  35. Kuroda H, Jamiyan T, Yamaguchi R, Kakumoto A, Abe A, Harada O, et al. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast. BMC Cancer. 2021;21:286 pubmed publisher
  36. Brune M, Stussi G, Lundberg P, Vela V, Heim D, Manz M, et al. Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. Ann Hematol. 2021;100:1169-1179 pubmed publisher
  37. Choi Y, Kim Y, Oh S, Suh K, Kim Y, Lee G, et al. Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer. Adv Sci (Weinh). 2021;8:2002497 pubmed publisher
  38. Can xe8 S, Van Snick J, Uyttenhove C, Pilotte L, van den Eynde B. TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism. J Immunother Cancer. 2021;9: pubmed publisher
  39. Zhang Y, Xiong D, Li Y, Xu G, Zhang B, Liu Y, et al. Schistosoma japonicum Infection in Treg-Specific USP21 Knockout Mice. J Immunol Res. 2021;2021:6613162 pubmed publisher
  40. Khosravi Maharlooei M, Li H, Hoelzl M, Zhao G, Ruiz A, Misra A, et al. Role of the thymus in spontaneous development of a multi-organ autoimmune disease in human immune system mice. J Autoimmun. 2021;119:102612 pubmed publisher
  41. Snyder M, Sembrat J, Noda K, MYERBURG M, Craig A, Mitash N, et al. Human Lung-Resident Macrophages Colocalize with and Provide Costimulation to PD1hi Tissue-Resident Memory T Cells. Am J Respir Crit Care Med. 2021;203:1230-1244 pubmed publisher
  42. Rodda L, Netland J, Shehata L, Pruner K, Morawski P, Thouvenel C, et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell. 2021;184:169-183.e17 pubmed publisher
  43. Luo B, Zhan Y, Luo M, Dong H, Liu J, Lin Y, et al. Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration. Cell Death Dis. 2020;11:973 pubmed publisher
  44. Bhattacharya P, Ellegård R, Khalid M, Svanberg C, Govender M, Keita A, et al. Complement opsonization of HIV affects primary infection of human colorectal mucosa and subsequent activation of T cells. elife. 2020;9: pubmed publisher
  45. Pasciuto E, Burton O, Roca C, Lagou V, Rajan W, Theys T, et al. Microglia Require CD4 T Cells to Complete the Fetal-to-Adult Transition. Cell. 2020;182:625-640.e24 pubmed publisher
  46. Oh D, Kwek S, Raju S, Li T, McCarthy E, Chow E, et al. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020;181:1612-1625.e13 pubmed publisher
  47. Kuhny M, Forbes L, Çakan E, Vega Loza A, Kostiuk V, Dinesh R, et al. Disease-associated CTNNBL1 mutation impairs somatic hypermutation by decreasing nuclear AID. J Clin Invest. 2020;: pubmed publisher
  48. Hanaoka H, Nishimoto T, Okazaki Y, Takeuchi T, Kuwana M. A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus. Arthritis Res Ther. 2020;22:88 pubmed publisher
  49. Kim M, Chung Y, Kim H, Woo J, Ahn S, Park S. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res. 2020;22:32 pubmed publisher
  50. Beziat V, Tavernier S, Chen Y, Ma C, Materna M, Laurence A, et al. Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome. J Exp Med. 2020;217: pubmed publisher
  51. Herrera Rios D, Mughal S, Teuber Hanselmann S, Pierscianek D, Sucker A, Jansen P, et al. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain. Front Immunol. 2020;11:120 pubmed publisher
  52. Bell L, Lenhart A, Rosenwald A, Monoranu C, Berberich Siebelt F. Lymphoid Aggregates in the CNS of Progressive Multiple Sclerosis Patients Lack Regulatory T Cells. Front Immunol. 2019;10:3090 pubmed publisher
  53. Boudewijns S, Bloemendal M, de Haas N, Westdorp H, Bol K, Schreibelt G, et al. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunol Immunother. 2020;69:477-488 pubmed publisher
  54. Helmink B, Reddy S, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549-555 pubmed publisher
  55. Shima T, Shimoda M, Shigenobu T, Ohtsuka T, Nishimura T, Emoto K, et al. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma. Cancer Sci. 2020;111:727-738 pubmed publisher
  56. Martínez Fábregas J, Wilmes S, Wang L, Hafer M, Pohler E, Lokau J, et al. Kinetics of cytokine receptor trafficking determine signaling and functional selectivity. elife. 2019;8: pubmed publisher
  57. Li Z, Wang H, Zeng Q, Yan J, Hu Y, Li H, et al. p65/miR-23a/CCL22 axis regulated regulatory T cells recruitment in hepatitis B virus positive hepatocellular carcinoma. Cancer Med. 2020;9:711-723 pubmed publisher
  58. Wang P, Qi X, Xu G, Liu J, Guo J, Li X, et al. CCL28 promotes locomotor recovery after spinal cord injury via recruiting regulatory T cells. Aging (Albany NY). 2019;11:7402-7415 pubmed publisher
  59. Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier Pfistershammer K, et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun. 2019;10:4186 pubmed publisher
  60. Fu D, Senouthai S, Wang J, You Y. Vasoactive intestinal peptide ameliorates renal injury in a pristane-induced lupus mouse model by modulating Th17/Treg balance. BMC Nephrol. 2019;20:350 pubmed publisher
  61. Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q, et al. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. J Immunother Cancer. 2019;7:233 pubmed publisher
  62. Di Blasi D, Boldanova T, Mori L, Terracciano L, Heim M, De Libero G. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol. 2020;9:195-218 pubmed publisher
  63. Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, et al. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019;178:795-806.e12 pubmed publisher
  64. Leclerc M, Voilin E, Gros G, Corgnac S, de Montpreville V, Validire P, et al. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nat Commun. 2019;10:3345 pubmed publisher
  65. Canete P, Sweet R, Gonzalez Figueroa P, Papa I, Ohkura N, Bolton H, et al. Regulatory roles of IL-10-producing human follicular T cells. J Exp Med. 2019;: pubmed publisher
  66. Del Duca E, Pavel A, Dubin C, Song T, Wallace E, Peng X, et al. Major Differences in Expression of Inflammatory Pathways in Skin from Different Body Sites of Healthy Individuals. J Invest Dermatol. 2019;139:2228-2232.e10 pubmed publisher
  67. Thauland T, Pellerin L, Ohgami R, Bacchetta R, Butte M. Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome. Front Immunol. 2019;10:753 pubmed publisher
  68. Lim S, Kim J, Jeon S, Shin M, Kwon J, Kim T, et al. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019;10:496 pubmed publisher
  69. Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177:1330-1345.e18 pubmed publisher
  70. Binnewies M, Mujal A, Pollack J, Combes A, Hardison E, Barry K, et al. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. Cell. 2019;177:556-571.e16 pubmed publisher
  71. Thompson P, Shah A, Ntranos V, Van Gool F, Atkinson M, Bhushan A. Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes. Cell Metab. 2019;29:1045-1060.e10 pubmed publisher
  72. Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature. 2019;566:270-274 pubmed publisher
  73. Wen Z, Jin K, Shen Y, Yang Z, Li Y, Wu B, et al. N-myristoyltransferase deficiency impairs activation of kinase AMPK and promotes synovial tissue inflammation. Nat Immunol. 2019;20:313-325 pubmed publisher
  74. Lavoie S, Conway K, Lassen K, Jijon H, Pan H, Chun E, et al. The Crohn's disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response. elife. 2019;8: pubmed publisher
  75. Ha D, Tanaka A, Kibayashi T, Tanemura A, Sugiyama D, Wing J, et al. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc Natl Acad Sci U S A. 2019;116:609-618 pubmed publisher
  76. Cornelissen L, Blanas A, van der Horst J, Kruijssen L, Zaal A, O Toole T, et al. Disruption of sialic acid metabolism drives tumor growth by augmenting CD8+ T cell apoptosis. Int J Cancer. 2019;144:2290-2302 pubmed publisher
  77. Richardson J, Armbruster N, Günter M, Henes J, Autenrieth S. Staphylococcus aureus PSM Peptides Modulate Human Monocyte-Derived Dendritic Cells to Prime Regulatory T Cells. Front Immunol. 2018;9:2603 pubmed publisher
  78. Williams P, Basu S, Garcia Manero G, Hourigan C, Oetjen K, Cortes J, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470-1481 pubmed publisher
  79. Wagner D, Amini L, Wendering D, Burkhardt L, Akyüz L, Reinke P, et al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat Med. 2019;25:242-248 pubmed publisher
  80. Kuranda K, Jean Alphonse P, Leborgne C, Hardet R, Collaud F, Marmier S, et al. Exposure to wild-type AAV drives distinct capsid immunity profiles in humans. J Clin Invest. 2018;128:5267-5279 pubmed publisher
  81. Hoang T, Harper J, Pino M, Wang H, Micci L, King C, et al. Bone Marrow-Derived CD4+ T Cells Are Depleted in Simian Immunodeficiency Virus-Infected Macaques and Contribute to the Size of the Replication-Competent Reservoir. J Virol. 2019;93: pubmed publisher
  82. Masuda J, Umemura C, Yokozawa M, Yamauchi K, Seko T, Yamashita M, et al. Dietary Supplementation of Selenoneine-Containing Tuna Dark Muscle Extract Effectively Reduces Pathology of Experimental Colorectal Cancers in Mice. Nutrients. 2018;10: pubmed publisher
  83. Patel N, Vukmanovic Stejic M, Suárez Fariñas M, Chambers E, Sandhu D, Fuentes Duculan J, et al. Impact of Zostavax Vaccination on T-Cell Accumulation and Cutaneous Gene Expression in the Skin of Older Humans After Varicella Zoster Virus Antigen-Specific Challenge. J Infect Dis. 2018;218:S88-S98 pubmed publisher
  84. Tai Y, Lin L, Xing L, Cho S, Yu T, Acharya C, et al. APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 2019;33:426-438 pubmed publisher
  85. Zhao S, Ding J, Wang S, Li C, Guo P, Zhang M, et al. Decreased expression of circulating Aire and increased Tfh/Tfr cells in myasthenia gravis patients. Biosci Rep. 2018;38: pubmed publisher
  86. Sayin I, Radtke A, Vella L, Jin W, Wherry E, Buggert M, et al. Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med. 2018;215:1531-1542 pubmed publisher
  87. Ondigo B, Ndombi E, Nicholson S, Oguso J, Carter J, Kittur N, et al. Functional Studies of T Regulatory Lymphocytes in Human Schistosomiasis in Western Kenya. Am J Trop Med Hyg. 2018;98:1770-1781 pubmed publisher
  88. Varelias A, Bunting M, Ormerod K, Koyama M, Olver S, Straube J, et al. Recipient mucosal-associated invariant T cells control GVHD within the colon. J Clin Invest. 2018;128:1919-1936 pubmed publisher
  89. Han Y, Liu Q, Hou J, Gu Y, Zhang Y, Chen Z, et al. Tumor-Induced Generation of Splenic Erythroblast-like Ter-Cells Promotes Tumor Progression. Cell. 2018;173:634-648.e12 pubmed publisher
  90. Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine T, et al. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J Clin Invest. 2018;128:2487-2499 pubmed publisher
  91. Macdougall C, Wood E, Loschko J, Scagliotti V, Cassidy F, Robinson M, et al. Visceral Adipose Tissue Immune Homeostasis Is Regulated by the Crosstalk between Adipocytes and Dendritic Cell Subsets. Cell Metab. 2018;27:588-601.e4 pubmed publisher
  92. Qu S, Xue H, Dong X, Lin D, Wu R, Nabavi N, et al. Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. Int J Cancer. 2018;143:419-429 pubmed publisher
  93. Hsieh W, Hsu T, Chang Y, Lai M. IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells. Nat Commun. 2018;9:463 pubmed publisher
  94. Lu Y, Kim N, Jiang Y, Zhang H, Zheng D, Zhu F, et al. Cambogin suppresses dextran sulphate sodium-induced colitis by enhancing Treg cell stability and function. Br J Pharmacol. 2018;175:1085-1099 pubmed publisher
  95. Amodio D, Cotugno N, Macchiarulo G, Rocca S, Dimopoulos Y, Castrucci M, et al. Quantitative Multiplexed Imaging Analysis Reveals a Strong Association between Immunogen-Specific B Cell Responses and Tonsillar Germinal Center Immune Dynamics in Children after Influenza Vaccination. J Immunol. 2018;200:538-550 pubmed publisher
  96. Mailer R, Gisterå A, Polyzos K, Ketelhuth D, Hansson G. Hypercholesterolemia Enhances T Cell Receptor Signaling and Increases the Regulatory T Cell Population. Sci Rep. 2017;7:15655 pubmed publisher
  97. Blom S, Paavolainen L, Bychkov D, Turkki R, Mäki Teeri P, Hemmes A, et al. Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. Sci Rep. 2017;7:15580 pubmed publisher
  98. Carvajal Hausdorf D, Mani N, Velcheti V, Schalper K, Rimm D. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. J Immunother Cancer. 2017;5:81 pubmed publisher
  99. Matsuyama K, Mizutani Y, Takahashi T, Shu E, Kanoh H, Miyazaki T, et al. Enhanced dendritic cells and regulatory T cells in the dermis of porokeratosis. Arch Dermatol Res. 2017;309:749-756 pubmed publisher
  100. Liaskou E, Jeffery L, Chanouzas D, Soskic B, Seldin M, Harper L, et al. Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals. Sci Rep. 2017;7:7652 pubmed publisher
  101. Funken D, Ishikawa Ankerhold H, Uhl B, Lerchenberger M, Rentsch M, Mayr D, et al. In situ targeting of dendritic cells sets tolerogenic environment and ameliorates CD4+ T-cell response in the postischemic liver. FASEB J. 2017;31:4796-4808 pubmed publisher
  102. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed publisher
  103. Dias J, Leeansyah E, Sandberg J. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. Proc Natl Acad Sci U S A. 2017;114:E5434-E5443 pubmed publisher
  104. Zheng C, Zheng L, Yoo J, Guo H, Zhang Y, Guo X, et al. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell. 2017;169:1342-1356.e16 pubmed publisher
  105. Garcia Hernandez M, Uribe Uribe N, Espinosa González R, Kast W, Khader S, Rangel Moreno J. A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression. Front Immunol. 2017;8:563 pubmed publisher
  106. Hasan Z, Koizumi S, Sasaki D, Yamada H, Arakaki N, Fujihara Y, et al. JunB is essential for IL-23-dependent pathogenicity of Th17 cells. Nat Commun. 2017;8:15628 pubmed publisher
  107. Ventura E, Weller M, Burghardt I. Cutting Edge: ERK1 Mediates the Autocrine Positive Feedback Loop of TGF-? and Furin in Glioma-Initiating Cells. J Immunol. 2017;198:4569-4574 pubmed publisher
  108. Angelin A, Gil de Gómez L, Dahiya S, Jiao J, Guo L, Levine M, et al. Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. Cell Metab. 2017;25:1282-1293.e7 pubmed publisher
  109. Huang A, Postow M, Orlowski R, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545:60-65 pubmed publisher
  110. Zanin Zhorov A, Weiss J, Trzeciak A, Chen W, Zhang J, Nyuydzefe M, et al. Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. J Immunol. 2017;198:3809-3814 pubmed publisher
  111. Melis D, Carbone F, Minopoli G, La Rocca C, Perna F, De Rosa V, et al. Cutting Edge: Increased Autoimmunity Risk in Glycogen Storage Disease Type 1b Is Associated with a Reduced Engagement of Glycolysis in T Cells and an Impaired Regulatory T Cell Function. J Immunol. 2017;198:3803-3808 pubmed publisher
  112. Su S, Liao J, Liu J, Huang D, He C, Chen F, et al. Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. Cell Res. 2017;27:461-482 pubmed publisher
  113. Szabo P, Goswami A, Mazzuca D, Kim K, O Gorman D, Hess D, et al. Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology. J Immunol. 2017;198:2805-2818 pubmed publisher
  114. Jeffery H, Jeffery L, Lutz P, Corrigan M, Webb G, Hirschfield G, et al. Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. Clin Exp Immunol. 2017;188:394-411 pubmed publisher
  115. Rao D, Gurish M, Marshall J, Slowikowski K, Fonseka C, Liu Y, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542:110-114 pubmed publisher
  116. Kempińska Podhorodecka A, Milkiewicz M, Wasik U, Ligocka J, Zawadzki M, Krawczyk M, et al. Decreased Expression of Vitamin D Receptor Affects an Immune Response in Primary Biliary Cholangitis via the VDR-miRNA155-SOCS1 Pathway. Int J Mol Sci. 2017;18: pubmed publisher
  117. Yanagita T, Murata Y, Tanaka D, Motegi S, Arai E, Daniwijaya E, et al. Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight. 2017;2:e89140 pubmed publisher
  118. Kim J, Kwon C, Joh J, Sinn D, Choi G, Park J, et al. Differences in Peripheral Blood Lymphocytes between Brand-Name and Generic Tacrolimus Used in Stable Liver Transplant Recipients. Med Princ Pract. 2017;26:221-228 pubmed publisher
  119. Boardman D, Philippeos C, Fruhwirth G, Ibrahim M, Hannen R, Cooper D, et al. Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection. Am J Transplant. 2017;17:931-943 pubmed publisher
  120. Lévy R, Okada S, Béziat V, Moriya K, Liu C, Chai L, et al. Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency. Proc Natl Acad Sci U S A. 2016;113:E8277-E8285 pubmed publisher
  121. Zhu H, Hu F, Sun X, Zhang X, Zhu L, Liu X, et al. CD16+ Monocyte Subset Was Enriched and Functionally Exacerbated in Driving T-Cell Activation and B-Cell Response in Systemic Lupus Erythematosus. Front Immunol. 2016;7:512 pubmed
  122. Wei C, Mei J, Tang L, Liu Y, Li D, Li M, et al. 1-Methyl-tryptophan attenuates regulatory T cells differentiation due to the inhibition of estrogen-IDO1-MRC2 axis in endometriosis. Cell Death Dis. 2016;7:e2489 pubmed publisher
  123. Senbabaoglu Y, Gejman R, Winer A, Liu M, Van Allen E, de Velasco G, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016;17:231 pubmed
  124. Sundara Y, Kostine M, Cleven A, Bovee J, Schilham M, Cleton Jansen A. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother. 2017;66:119-128 pubmed publisher
  125. Li J, Shayan G, Avery L, Jie H, Gildener Leapman N, Schmitt N, et al. Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology. 2016;5:e1200778 pubmed
  126. Weingartner E, Courneya J, Keegan A, Golding A. A novel method for assaying human regulatory T cell direct suppression of B cell effector function. J Immunol Methods. 2017;441:1-7 pubmed publisher
  127. Shifrin N, Kissiov D, Ardolino M, Joncker N, Raulet D. Differential Role of Hematopoietic and Nonhematopoietic Cell Types in the Regulation of NK Cell Tolerance and Responsiveness. J Immunol. 2016;197:4127-4136 pubmed publisher
  128. Peters C, Häsler R, Wesch D, Kabelitz D. Human Vδ2 T cells are a major source of interleukin-9. Proc Natl Acad Sci U S A. 2016;113:12520-12525 pubmed
  129. Dyer W, Tan J, Day T, Kiers L, Kiernan M, Yiannikas C, et al. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. Brain Behav. 2016;6:e00516 pubmed
  130. Kaewkangsadan V, Verma C, Eremin J, Cowley G, Ilyas M, Eremin O. Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. J Immunol Res. 2016;2016:4757405 pubmed
  131. Nagase H, Takeoka T, Urakawa S, Morimoto Okazawa A, Kawashima A, Iwahori K, et al. ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017;140:686-695 pubmed publisher
  132. Ogiya R, Niikura N, Kumaki N, Bianchini G, Kitano S, Iwamoto T, et al. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci. 2016;107:1730-1735 pubmed publisher
  133. Wang Y, Ma C, Ling Y, Bousfiha A, Camcioglu Y, Jacquot S, et al. Dual T cell- and B cell-intrinsic deficiency in humans with biallelic RLTPR mutations. J Exp Med. 2016;213:2413-2435 pubmed
  134. Klarquist J, Tobin K, Farhangi Oskuei P, Henning S, Fernandez M, Dellacecca E, et al. Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma. Cancer Res. 2016;76:6230-6240 pubmed
  135. Pachnio A, Ciáurriz M, Begum J, Lal N, Zuo J, Beggs A, et al. Cytomegalovirus Infection Leads to Development of High Frequencies of Cytotoxic Virus-Specific CD4+ T Cells Targeted to Vascular Endothelium. PLoS Pathog. 2016;12:e1005832 pubmed publisher
  136. Javvadi L, Parachuru V, Milne T, Seymour G, Rich A. Regulatory T-cells and IL17A(+) cells infiltrate oral lichen planus lesions. Pathology. 2016;48:564-73 pubmed publisher
  137. Jou Y, Tsai Y, Lin C, Tung C, Shen C, Tsai H, et al. Foxp3 enhances HIF-1α target gene expression in human bladder cancer through decreasing its ubiquitin-proteasomal degradation. Oncotarget. 2016;7:65403-65417 pubmed publisher
  138. Chopra M, Biehl M, Steinfatt T, Brandl A, Kums J, Amich J, et al. Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. J Exp Med. 2016;213:1881-900 pubmed publisher
  139. Torrelo A, Noguera Morel L, Hernandez Martin A, Clemente D, Barja J, Buzon L, et al. Recurrent lipoatrophic panniculitis of children. J Eur Acad Dermatol Venereol. 2017;31:536-543 pubmed publisher
  140. Cheng H, Gaddis D, Wu R, McSkimming C, Haynes L, Taylor A, et al. Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis. J Clin Invest. 2016;126:3236-46 pubmed publisher
  141. Chen H, Händel N, Ngeow J, Muller J, Huhn M, Yang H, et al. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells. J Allergy Clin Immunol. 2017;139:607-620.e15 pubmed publisher
  142. Miyan M, Schmidt Mende J, Kiessling R, Poschke I, de Boniface J. Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer. J Transl Med. 2016;14:227 pubmed publisher
  143. Baras A, Drake C, Liu J, Gandhi N, Kates M, Hoque M, et al. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology. 2016;5:e1134412 pubmed publisher
  144. Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, et al. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clin Cancer Res. 2017;23:149-158 pubmed publisher
  145. Orta Mascaró M, Consuegra Fernández M, Carreras E, Roncagalli R, Carreras Sureda A, Alvarez P, et al. CD6 modulates thymocyte selection and peripheral T cell homeostasis. J Exp Med. 2016;213:1387-97 pubmed publisher
  146. Brinkman C, Iwami D, Hritzo M, Xiong Y, Ahmad S, Simon T, et al. Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration. Nat Commun. 2016;7:12021 pubmed publisher
  147. Gu L, Deng W, Sun X, Zhou H, Xu Q. Rapamycin ameliorates CCl4-induced liver fibrosis in mice through reciprocal regulation of the Th17/Treg cell balance. Mol Med Rep. 2016;14:1153-61 pubmed publisher
  148. Liu Y, Xia T, Jin C, Gu D, Yu J, Shi W, et al. FOXP3 and CEACAM6 expression and T cell infiltration in the occurrence and development of colon cancer. Oncol Lett. 2016;11:3693-3701 pubmed
  149. Chu H, Khosravi A, Kusumawardhani I, Kwon A, Vasconcelos A, Cunha L, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science. 2016;352:1116-20 pubmed publisher
  150. Akyol Erikci A, Karagoz B, Bilgi O. Regulatory T Cells in Patients with Idiopathic Thrombocytopenic Purpura. Turk J Haematol. 2016;33:153-5 pubmed publisher
  151. Zhang H, Prado K, Zhang K, Peek E, Lee J, Wang X, et al. Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance. Clin Cancer Res. 2016;22:5349-5361 pubmed
  152. Stikvoort A, Sundin M, Uzunel M, Gertow J, Sundberg B, Schaffer M, et al. Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?. PLoS ONE. 2016;11:e0154737 pubmed publisher
  153. Cook A, McDonnell A, Lake R, Nowak A. Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. Oncoimmunology. 2016;5:e1066062 pubmed
  154. Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S, et al. PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. PLoS ONE. 2016;11:e0153954 pubmed publisher
  155. Goldstein J, Burlion A, Zaragoza B, Sendeyo K, Polansky J, Huehn J, et al. Inhibition of the JAK/STAT Signaling Pathway in Regulatory T Cells Reveals a Very Dynamic Regulation of Foxp3 Expression. PLoS ONE. 2016;11:e0153682 pubmed publisher
  156. Zwang N, Zhang R, Germana S, Fan M, Hastings W, Cao A, et al. Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways. Am J Transplant. 2016;16:2624-38 pubmed publisher
  157. Chen C, Liu Y, Hua M, Li X, Ji C, Ma D. Neuropathy correlated with imbalanced Foxp3/IL-17 in bone marrow microenvironment of patients with acute myeloid leukemia. Oncotarget. 2016;7:24455-65 pubmed publisher
  158. Macdonald K, Hoeppli R, Huang Q, Gillies J, Luciani D, Orban P, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016;126:1413-24 pubmed publisher
  159. Ladoire S, Enot D, Senovilla L, Ghiringhelli F, Poirier Colame V, Chaba K, et al. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy. 2016;12:864-75 pubmed publisher
  160. Apostolidis S, Rodríguez Rodríguez N, Suárez Fueyo A, Dioufa N, Ozcan E, Crispín J, et al. Phosphatase PP2A is requisite for the function of regulatory T cells. Nat Immunol. 2016;17:556-64 pubmed publisher
  161. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher
  162. Friedman K, Brodsky A, Lu S, Wood S, Gill A, Lombardo K, et al. Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. Mod Pathol. 2016;29:528-41 pubmed publisher
  163. Vermeulen J, Van Hecke W, Spliet W, Villacorta Hidalgo J, Fisch P, Broekhuizen R, et al. Pediatric Primitive Neuroectodermal Tumors of the Central Nervous System Differentially Express Granzyme Inhibitors. PLoS ONE. 2016;11:e0151465 pubmed publisher
  164. Seifert L, Werba G, Tiwari S, Giao Ly N, Nguy S, Alothman S, et al. Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. Gastroenterology. 2016;150:1659-1672.e5 pubmed publisher
  165. McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-9 pubmed publisher
  166. Leitch C, Natafji E, Yu C, Abdul Ghaffar S, Madarasingha N, Venables Z, et al. Filaggrin-null mutations are associated with increased maturation markers on Langerhans cells. J Allergy Clin Immunol. 2016;138:482-490.e7 pubmed publisher
  167. Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Rea D, Barbieri A, et al. A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice. J Transl Med. 2016;14:58 pubmed publisher
  168. Procaccini C, Carbone F, Di Silvestre D, Brambilla F, De Rosa V, Galgani M, et al. The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements. Immunity. 2016;44:406-21 pubmed publisher
  169. Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016;38:1074-84 pubmed publisher
  170. Legorreta Haquet M, Chávez Rueda K, Chávez Sánchez L, Cervera Castillo H, Zenteno Galindo E, Barile Fabris L, et al. Function of Treg Cells Decreased in Patients With Systemic Lupus Erythematosus Due To the Effect of Prolactin. Medicine (Baltimore). 2016;95:e2384 pubmed publisher
  171. Menter T, Dickenmann M, Juskevicius D, Steiger J, Dirnhofer S, Tzankov A. Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling. Hematol Oncol. 2017;35:187-197 pubmed publisher
  172. James E, Gates T, LaFond R, Yamamoto S, Ni C, Mai D, et al. Neuroinvasive West Nile Infection Elicits Elevated and Atypically Polarized T Cell Responses That Promote a Pathogenic Outcome. PLoS Pathog. 2016;12:e1005375 pubmed publisher
  173. Younis R, Han K, Webb T. Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells. J Immunol. 2016;196:1419-29 pubmed publisher
  174. Kim K, Wen X, Yang H, Kim W, Kang G. Prognostic Implication of M2 Macrophages Are Determined by the Proportional Balance of Tumor Associated Macrophages and Tumor Infiltrating Lymphocytes in Microsatellite-Unstable Gastric Carcinoma. PLoS ONE. 2015;10:e0144192 pubmed publisher
  175. Günther S, Ostheimer C, Stangl S, Specht H, Mózes P, Jesinghaus M, et al. Correlation of Hsp70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer. Front Immunol. 2015;6:556 pubmed publisher
  176. Kobayashi S, Watanabe T, Suzuki R, Furu M, Ito H, Ito J, et al. TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells. Eur J Immunol. 2016;46:360-71 pubmed publisher
  177. Vierboom M, Breedveld E, Kap Y, Mary C, Poirier N, t Hart B, et al. Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis. Clin Exp Immunol. 2016;183:405-18 pubmed publisher
  178. Laborel Préneron E, Bianchi P, Boralevi F, Lehours P, Fraysse F, Morice Picard F, et al. Effects of the Staphylococcus aureus and Staphylococcus epidermidis Secretomes Isolated from the Skin Microbiota of Atopic Children on CD4+ T Cell Activation. PLoS ONE. 2015;10:e0141067 pubmed publisher
  179. Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16:1235-44 pubmed publisher
  180. Feng Z, Puri S, Moudgil T, Wood W, Hoyt C, Wang C, et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer. 2015;3:47 pubmed publisher
  181. Miles B, Miller S, Folkvord J, Kimball A, Chamanian M, Meditz A, et al. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat Commun. 2015;6:8608 pubmed publisher
  182. Scottà C, Fanelli G, Hoong S, Romano M, Lamperti E, Sukthankar M, et al. Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica. 2016;101:91-100 pubmed publisher
  183. Zhao L, Li C, Jin P, Ng C, Lin Z, Li Y, et al. Histopathological features of sinonasal inverted papillomas in chinese patients. Laryngoscope. 2016;126:E141-7 pubmed publisher
  184. Liu K, Yang K, Wu B, Chen H, Chen X, Chen X, et al. Tumor-Infiltrating Immune Cells Are Associated With Prognosis of Gastric Cancer. Medicine (Baltimore). 2015;94:e1631 pubmed publisher
  185. Bézie S, Picarda E, Ossart J, Tesson L, Usal C, Renaudin K, et al. IL-34 is a Treg-specific cytokine and mediates transplant tolerance. J Clin Invest. 2015;125:3952-64 pubmed publisher
  186. Broos C, van Nimwegen M, Kleinjan A, Ten Berge B, Muskens F, In t Veen J, et al. Impaired survival of regulatory T cells in pulmonary sarcoidosis. Respir Res. 2015;16:108 pubmed publisher
  187. Vacchelli E, Semeraro M, Enot D, Chaba K, Poirier Colame V, Dartigues P, et al. Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. Oncotarget. 2015;6:20840-50 pubmed
  188. Gao Y, Zhang M, Li J, Yang M, Liu Y, Guo X, et al. Circulating FoxP3+ Regulatory T and Interleukin17-Producing Th17 Cells Actively Influence HBV Clearance in De Novo Hepatitis B Virus Infected Patients after Orthotopic Liver Transplantation. PLoS ONE. 2015;10:e0137881 pubmed publisher
  189. Wang W, Yen M, Liu K, Hsu P, Lin M, Chen P, et al. Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses. Stem Cell Reports. 2015;5:392-404 pubmed publisher
  190. Jasinski Bergner S, Stoehr C, Bukur J, Massa C, Braun J, Hüttelmaier S, et al. Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma. Oncoimmunology. 2015;4:e1008805 pubmed
  191. Suradhat S, Wongyanin P, Kesdangsakonwut S, Teankum K, Lumyai M, Triyarach S, et al. A novel DNA vaccine for reduction of PRRSV-induced negative immunomodulatory effects: A proof of concept. Vaccine. 2015;33:3997-4003 pubmed publisher
  192. Prata T, Bonin C, Ferreira A, Padovani C, Fernandes C, Machado A, et al. Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions. Immunology. 2015;146:113-21 pubmed publisher
  193. Horn T, Laus J, Seitz A, Maurer T, Schmid S, Wolf P, et al. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol. 2016;34:181-7 pubmed publisher
  194. Castiglioni A, Corna G, Rigamonti E, Basso V, Vezzoli M, Monno A, et al. FOXP3+ T Cells Recruited to Sites of Sterile Skeletal Muscle Injury Regulate the Fate of Satellite Cells and Guide Effective Tissue Regeneration. PLoS ONE. 2015;10:e0128094 pubmed publisher
  195. McArthur M, Fresnay S, Magder L, Darton T, Jones C, Waddington C, et al. Activation of Salmonella Typhi-specific regulatory T cells in typhoid disease in a wild-type S. Typhi challenge model. PLoS Pathog. 2015;11:e1004914 pubmed publisher
  196. Wang Z, Wei M, Zhang H, Chen H, Germana S, Huang C, et al. Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo. Mol Oncol. 2015;9:1458-70 pubmed publisher
  197. Liechtenstein T, Perez Janices N, Blanco Luquin I, Goyvaerts C, Schwarze J, Dufait I, et al. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology. 2014;3:e945378 pubmed
  198. Boer M, Prins C, van Meijgaarden K, van Dissel J, Ottenhoff T, Joosten S. Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults. Clin Vaccine Immunol. 2015;22:778-88 pubmed publisher
  199. DaFonseca S, Niessl J, Pouvreau S, Wacleche V, Gosselin A, Cleret Buhot A, et al. Impaired Th17 polarization of phenotypically naive CD4(+) T-cells during chronic HIV-1 infection and potential restoration with early ART. Retrovirology. 2015;12:38 pubmed publisher
  200. Anandasabapathy N, Breton G, Hurley A, Caskey M, Trumpfheller C, Sarma P, et al. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015;50:924-30 pubmed publisher
  201. Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520:692-6 pubmed publisher
  202. Weinberg A, Muresan P, Richardson K, Fenton T, Domínguez T, Bloom A, et al. Determinants of vaccine immunogenicity in HIV-infected pregnant women: analysis of B and T cell responses to pandemic H1N1 monovalent vaccine. PLoS ONE. 2015;10:e0122431 pubmed publisher
  203. Rochman Y, Yukawa M, Kartashov A, Barski A. Functional characterization of human T cell hyporesponsiveness induced by CTLA4-Ig. PLoS ONE. 2015;10:e0122198 pubmed publisher
  204. Punt S, van Vliet M, Spaans V, de Kroon C, Fleuren G, Gorter A, et al. FoxP3(+) and IL-17(+) cells are correlated with improved prognosis in cervical adenocarcinoma. Cancer Immunol Immunother. 2015;64:745-53 pubmed publisher
  205. Romani R, Pirisinu I, Calvitti M, Pallotta M, Gargaro M, Bistoni G, et al. Stem cells from human amniotic fluid exert immunoregulatory function via secreted indoleamine 2,3-dioxygenase1. J Cell Mol Med. 2015;19:1593-605 pubmed publisher
  206. Obiero J, Shekalaghe S, Hermsen C, Mpina M, Bijker E, Roestenberg M, et al. Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection. Infect Immun. 2015;83:2185-96 pubmed publisher
  207. Bowcutt R, Malter L, Chen L, Wolff M, Robertson I, Rifkin D, et al. Isolation and cytokine analysis of lamina propria lymphocytes from mucosal biopsies of the human colon. J Immunol Methods. 2015;421:27-35 pubmed publisher
  208. Kim Y, Lim H, Jung H, Wetsel R, Chung Y. Regulation of autoimmune germinal center reactions in lupus-prone BXD2 mice by follicular helper T cells. PLoS ONE. 2015;10:e0120294 pubmed publisher
  209. Nouël A, Pochard P, Simon Q, Ségalen I, Le Meur Y, Pers J, et al. B-Cells induce regulatory T cells through TGF-β/IDO production in A CTLA-4 dependent manner. J Autoimmun. 2015;59:53-60 pubmed publisher
  210. Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, et al. The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. Clin Cancer Res. 2015;21:2840-50 pubmed publisher
  211. Severson J, Serracino H, Mateescu V, Raeburn C, McIntyre R, Sams S, et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-30 pubmed publisher
  212. Hsiao H, Hsu T, Liu W, Hsieh W, Chou T, Wu Y, et al. Deltex1 antagonizes HIF-1α and sustains the stability of regulatory T cells in vivo. Nat Commun. 2015;6:6353 pubmed publisher
  213. Torres Cabala C, Curry J, Li Ning Tapia E, Ramos C, Tetzlaff M, Prieto V, et al. HTLV-1-associated infective dermatitis demonstrates low frequency of FOXP3-positive T-regulatory lymphocytes. J Dermatol Sci. 2015;77:150-5 pubmed publisher
  214. Valle A, Barbagiovanni G, Jofra T, Stabilini A, Pérol L, Baeyens A, et al. Heterogeneous CD3 expression levels in differing T cell subsets correlate with the in vivo anti-CD3-mediated T cell modulation. J Immunol. 2015;194:2117-27 pubmed publisher
  215. Bhela S, Kempsell C, Manohar M, Dominguez Villar M, Griffin R, Bhatt P, et al. Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol. 2015;194:2180-9 pubmed publisher
  216. Crncec I, Pathria P, Svinka J, Eferl R. Induction of colorectal cancer in mice and histomorphometric evaluation of tumors. Methods Mol Biol. 2015;1267:145-64 pubmed publisher
  217. Engels C, Charehbili A, van de Velde C, Bastiaannet E, Sajet A, Putter H, et al. The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. Breast Cancer Res Treat. 2015;149:587-96 pubmed publisher
  218. Däster S, Eppenberger Castori S, Hirt C, Zlobec I, Delko T, Nebiker C, et al. High frequency of CD8 positive lymphocyte infiltration correlates with lack of lymph node involvement in early rectal cancer. Dis Markers. 2014;2014:792183 pubmed publisher
  219. Vorobjova T, Uibo O, Heilman K, Uibo R. Increased density of tolerogenic dendritic cells in the small bowel mucosa of celiac patients. World J Gastroenterol. 2015;21:439-52 pubmed publisher
  220. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015;25:208-24 pubmed publisher
  221. Yu A, Snowhite I, Vendrame F, Rosenzwajg M, Klatzmann D, Pugliese A, et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes. 2015;64:2172-83 pubmed publisher
  222. Hildebrand A, Jarsch C, Kern Y, Böhringer D, Reinhard T, Schwartzkopff J. Subconjunctivally applied naïve Tregs support corneal graft survival in baby rats. Mol Vis. 2014;20:1749-57 pubmed
  223. Li F, Ji L, Wang W, Hua F, Zhan Y, Zou S, et al. Insufficient secretion of IL-10 by Tregs compromised its control on over-activated CD4+ T effector cells in newly diagnosed adult immune thrombocytopenia patients. Immunol Res. 2015;61:269-80 pubmed publisher
  224. Hatano R, Ohnuma K, Otsuka H, Komiya E, Taki I, Iwata S, et al. CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway. J Immunol. 2015;194:960-72 pubmed publisher
  225. Nguyen L, Pan J, Dinh T, Hadeiba H, O Hara E, Ebtikar A, et al. Role and species-specific expression of colon T cell homing receptor GPR15 in colitis. Nat Immunol. 2015;16:207-213 pubmed publisher
  226. Wu Y, Du Z, Cai Y, Peng W, Zheng G, Zheng G, et al. Effective expansion of forkhead box P3⁺ regulatory T cells via early secreted antigenic target 6 and antigen 85 complex B from Mycobacterium tuberculosis. Mol Med Rep. 2015;11:3134-42 pubmed publisher
  227. Rutz S, Kayagaki N, Phung Q, Eidenschenk C, Noubade R, Wang X, et al. Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cells. Nature. 2015;518:417-21 pubmed publisher
  228. Kong L, Wei J, Haider A, Liebelt B, Ling X, Conrad C, et al. Therapeutic targets in subependymoma. J Neuroimmunol. 2014;277:168-75 pubmed publisher
  229. Cousens L, Najafian N, Martin W, De Groot A. Tregitope: Immunomodulation powerhouse. Hum Immunol. 2014;75:1139-46 pubmed publisher
  230. Rueda C, Wells C, Gisslen T, Jobe A, Kallapur S, Chougnet C. Effect of chorioamnionitis on regulatory T cells in moderate/late preterm neonates. Hum Immunol. 2015;76:65-73 pubmed publisher
  231. Huss D, Mehta D, Sharma A, You X, Riester K, Sheridan J, et al. In vivo maintenance of human regulatory T cells during CD25 blockade. J Immunol. 2015;194:84-92 pubmed
  232. Willmann K, Klaver S, DoÄŸu F, Santos Valente E, Garncarz W, Bilic I, et al. Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nat Commun. 2014;5:5360 pubmed publisher
  233. Dominguez Villar M, Gautron A, de Marcken M, Keller M, Hafler D. TLR7 induces anergy in human CD4(+) T cells. Nat Immunol. 2015;16:118-28 pubmed publisher
  234. Thompson I, Mann E, Stokes M, English N, Knight S, Williamson D. Specific activation of dendritic cells enhances clearance of Bacillus anthracis following infection. PLoS ONE. 2014;9:e109720 pubmed publisher
  235. Hermans C, Anz D, Engel J, Kirchner T, Endres S, Mayr D. Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers. PLoS ONE. 2014;9:e111757 pubmed publisher
  236. Llosa N, Cruise M, Tam A, Wicks E, Hechenbleikner E, Taube J, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43-51 pubmed publisher
  237. Thauland T, Koguchi Y, Dustin M, Parker D. CD28-CD80 interactions control regulatory T cell motility and immunological synapse formation. J Immunol. 2014;193:5894-903 pubmed publisher
  238. Freeman A, Bridge J, Maruthayanar P, Overgaard N, Jung J, Simpson F, et al. Comparative immune phenotypic analysis of cutaneous Squamous Cell Carcinoma and Intraepidermal Carcinoma in immune-competent individuals: proportional representation of CD8+ T-cells but not FoxP3+ Regulatory T-cells is associated with disease stage. PLoS ONE. 2014;9:e110928 pubmed publisher
  239. Xie L, Choudhury G, Winters A, Yang S, Jin K. Cerebral regulatory T cells restrain microglia/macrophage-mediated inflammatory responses via IL-10. Eur J Immunol. 2015;45:180-91 pubmed publisher
  240. Weed D, Vella J, Reis I, De La Fuente A, Gomez C, Sargi Z, et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21:39-48 pubmed publisher
  241. Bacher P, Kniemeyer O, Teutschbein J, Thön M, Vödisch M, Wartenberg D, et al. Identification of immunogenic antigens from Aspergillus fumigatus by direct multiparameter characterization of specific conventional and regulatory CD4+ T cells. J Immunol. 2014;193:3332-43 pubmed publisher
  242. Jin J, Zhang W, Wong K, Kwak M, van Driel I, Yu Q. Inhibition of breast cancer resistance protein (ABCG2) in human myeloid dendritic cells induces potent tolerogenic functions during LPS stimulation. PLoS ONE. 2014;9:e104753 pubmed publisher
  243. Bending D, Pesenacker A, Ursu S, Wu Q, Lom H, Thirugnanabalan B, et al. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J Immunol. 2014;193:2699-708 pubmed publisher
  244. Zhang X, Gao L, Liang X, Guo M, Wang R, Pan Y, et al. HBV preS2 transactivates FOXP3 expression in malignant hepatocytes. Liver Int. 2015;35:1087-94 pubmed publisher
  245. Skogberg G, Lundberg V, Lindgren S, Gudmundsdottir J, Sandström K, Kämpe O, et al. Altered expression of autoimmune regulator in infant down syndrome thymus, a possible contributor to an autoimmune phenotype. J Immunol. 2014;193:2187-95 pubmed publisher
  246. Noyan F, Lee Y, Zimmermann K, Hardtke Wolenski M, Taubert R, Warnecke G, et al. Isolation of human antigen-specific regulatory T cells with high suppressive function. Eur J Immunol. 2014;44:2592-602 pubmed publisher
  247. Kim K, Chung B, Kim B, Cho M, Yang C. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients. Immunology. 2015;144:68-78 pubmed publisher
  248. Gupta M, Kolli D, Molteni C, Casola A, Garofalo R. Paramyxovirus infection regulates T cell responses by BDCA-1+ and BDCA-3+ myeloid dendritic cells. PLoS ONE. 2014;9:e99227 pubmed publisher
  249. Azzimonti B, Zavattaro E, Provasi M, Vidali M, Conca A, Catalano E, et al. Intense Foxp3+ CD25+ regulatory T-cell infiltration is associated with high-grade cutaneous squamous cell carcinoma and counterbalanced by CD8+/Foxp3+ CD25+ ratio. Br J Dermatol. 2015;172:64-73 pubmed publisher
  250. Jitschin R, Braun M, Büttner M, Dettmer Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124:750-60 pubmed publisher
  251. Hodi F, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2:632-42 pubmed publisher
  252. Gautron A, Dominguez Villar M, de Marcken M, Hafler D. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells. Eur J Immunol. 2014;44:2703-2711 pubmed publisher
  253. Bedke T, Iannitti R, De Luca A, Giovannini G, Fallarino F, Berges C, et al. Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and mice. Immunol Cell Biol. 2014;92:659-70 pubmed publisher
  254. Luciano A, Arbona Ramirez I, Ruiz R, Llorens Bonilla B, Martinez Lopez D, Funderburg N, et al. Alterations in regulatory T cell subpopulations seen in preterm infants. PLoS ONE. 2014;9:e95867 pubmed publisher
  255. Grage Griebenow E, Jerg E, Gorys A, Wicklein D, Wesch D, Freitag Wolf S, et al. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Mol Oncol. 2014;8:982-97 pubmed publisher
  256. Kuwahara M, Suzuki J, Tofukuji S, Yamada T, Kanoh M, Matsumoto A, et al. The Menin-Bach2 axis is critical for regulating CD4 T-cell senescence and cytokine homeostasis. Nat Commun. 2014;5:3555 pubmed publisher
  257. Ito S, Bollard C, Carlsten M, Melenhorst J, Biancotto A, Wang E, et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol Ther. 2014;22:1388-1395 pubmed publisher
  258. Keswani T, Bhattacharyya A. Differential role of T regulatory and Th17 in Swiss mice infected with Plasmodium berghei ANKA and Plasmodium yoelii. Exp Parasitol. 2014;141:82-92 pubmed publisher
  259. Berney Meyer L, Hung N, Slatter T, Schollum J, Kitching A, Walker R. Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury?. Nephrology (Carlton). 2014;19:359-65 pubmed publisher
  260. Peguillet I, Milder M, Louis D, Vincent Salomon A, Dorval T, Piperno Neumann S, et al. High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res. 2014;74:2204-16 pubmed publisher
  261. Sereti I, Estes J, Thompson W, Morcock D, Fischl M, Croughs T, et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog. 2014;10:e1003890 pubmed publisher
  262. Naviglio S, Arrigo S, Martelossi S, Villanacci V, Tommasini A, Loganes C, et al. Severe inflammatory bowel disease associated with congenital alteration of transforming growth factor beta signaling. J Crohns Colitis. 2014;8:770-4 pubmed publisher
  263. Wolfs T, Kramer B, Thuijls G, Kemp M, Saito M, Willems M, et al. Chorioamnionitis-induced fetal gut injury is mediated by direct gut exposure of inflammatory mediators or by lung inflammation. Am J Physiol Gastrointest Liver Physiol. 2014;306:G382-93 pubmed publisher
  264. Park S, Veerapu N, Shin E, Biancotto A, McCoy J, Capone S, et al. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med. 2013;19:1638-42 pubmed publisher
  265. Shaw J, Hunt P, Critchfield J, McConnell D, Garcia J, Pollard R, et al. Short communication: HIV+ viremic slow progressors maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activation. AIDS Res Hum Retroviruses. 2013;29:172-7 pubmed publisher
  266. Wolff M, Leung J, Davenport M, Poles M, Cho I, Loke P. TH17, TH22 and Treg cells are enriched in the healthy human cecum. PLoS ONE. 2012;7:e41373 pubmed publisher
  267. Nicholson I, Mavrangelos C, Bird D, Bresatz Atkins S, Eastaff Leung N, Grose R, et al. PI16 is expressed by a subset of human memory Treg with enhanced migration to CCL17 and CCL20. Cell Immunol. 2012;275:12-8 pubmed publisher
  268. Koreth J, Matsuoka K, Kim H, McDonough S, Bindra B, Alyea E, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365:2055-66 pubmed publisher
  269. Shaw J, Hunt P, Critchfield J, McConnell D, Garcia J, Pollard R, et al. Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol. 2011;85:11422-34 pubmed publisher
  270. Caramori G, Lasagna L, Casalini A, Adcock I, Casolari P, Contoli M, et al. Immune response to Mycobacterium tuberculosis infection in the parietal pleura of patients with tuberculous pleurisy. PLoS ONE. 2011;6:e22637 pubmed publisher
  271. Ruffell B, Au A, Rugo H, Esserman L, Hwang E, Coussens L. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012;109:2796-801 pubmed publisher
  272. West N, Panet Raymond V, Truong P, Alexander C, Babinszky S, Milne K, et al. Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR). Breast Cancer (Auckl). 2011;5:105-15 pubmed publisher
  273. Gadiot J, Hooijkaas A, Kaiser A, Van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2011;117:2192-201 pubmed publisher
  274. Wu Y, Ren M, Yang R, Liang X, Ma Y, Tang Y, et al. Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+ Th/Treg cell subset imbalance in ankylosing spondylitis. Arthritis Res Ther. 2011;13:R29 pubmed publisher
  275. Antonelli L, Mahnke Y, Hodge J, Porter B, Barber D, DerSimonian R, et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood. 2010;116:3818-27 pubmed publisher
  276. French J, Weber Z, Fretwell D, Said S, Klopper J, Haugen B. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2325-33 pubmed publisher
  277. Markley J, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood. 2010;115:3508-19 pubmed publisher
  278. Oo Y, Weston C, Lalor P, Curbishley S, Withers D, Reynolds G, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol. 2010;184:2886-98 pubmed publisher
  279. Hunter P, Nistala K, Jina N, Eddaoudi A, Thomson W, Hubank M, et al. Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression. Arthritis Rheum. 2010;62:896-907 pubmed publisher
  280. Amarnath S, Costanzo C, Mariotti J, Ullman J, Telford W, Kapoor V, et al. Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol. 2010;8:e1000302 pubmed publisher
  281. Antiga E, Quaglino P, Bellandi S, Volpi W, Del Bianco E, Comessatti A, et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol. 2010;162:1056-63 pubmed publisher
  282. Houot R, Goldstein M, Kohrt H, Myklebust J, Alizadeh A, Lin J, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood. 2009;114:3431-8 pubmed publisher
  283. Ellestad K, Tsutsui S, Noorbakhsh F, Warren K, Yong V, Pittman Q, et al. Early life exposure to lipopolysaccharide suppresses experimental autoimmune encephalomyelitis by promoting tolerogenic dendritic cells and regulatory T cells. J Immunol. 2009;183:298-309 pubmed publisher
  284. Sivasankar B, Longhi M, Gallagher K, Betts G, Morgan B, Godkin A, et al. CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?. J Immunol. 2009;182:5203-7 pubmed publisher
  285. Milne K, Barnes R, Girardin A, Mawer M, Nesslinger N, Ng A, et al. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS ONE. 2008;3:e3409 pubmed publisher
  286. Fujimaki W, Takahashi N, Ohnuma K, Nagatsu M, Kurosawa H, Yoshida S, et al. Comparative study of regulatory T cell function of human CD25CD4 T cells from thymocytes, cord blood, and adult peripheral blood. Clin Dev Immunol. 2008;2008:305859 pubmed publisher
  287. Koenen H, Smeets R, Vink P, van Rijssen E, Boots A, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 2008;112:2340-52 pubmed publisher
  288. Ebert L, Tan B, Browning J, Svobodova S, Russell S, Kirkpatrick N, et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res. 2008;68:3001-9 pubmed publisher
  289. Pereira L, Villinger F, Wulff H, Sankaranarayanan A, Raman G, Ansari A. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp Biol Med (Maywood). 2007;232:1338-54 pubmed
  290. Kang S, Lim H, Andrisani O, Broxmeyer H, Kim C. Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells. J Immunol. 2007;179:3724-33 pubmed
  291. Yates J, Rovis F, Mitchell P, Afzali B, Tsang J, Garin M, et al. The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol. 2007;19:785-99 pubmed
  292. Zuber J, Viguier M, Lemaitre F, Senée V, Patey N, Elain G, et al. Severe FOXP3+ and naïve T lymphopenia in a non-IPEX form of autoimmune enteropathy combined with an immunodeficiency. Gastroenterology. 2007;132:1694-704 pubmed
  293. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110:1225-32 pubmed
  294. Yu Q, Saruta M, Avanesyan A, Fleshner P, Banham A, Papadakis K. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis. 2007;13:191-9 pubmed
  295. Lim H, Broxmeyer H, Kim C. Regulation of trafficking receptor expression in human forkhead box P3+ regulatory T cells. J Immunol. 2006;177:840-51 pubmed